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Abstract
Background. The incidence of infective endocarditis is progressively rising among people
who inject drugs.
Methods. A retrospective cohort study was conducted using data from electronic medical
records to characterize important predictors that contribute to the recurrence of infective
endocarditis and evaluate the associations of survival time and predictors of interest in the
presence of competing risks among people who inject drugs. Multivariate logistic and
survival regression analyses were carried out to identify factors associated with infective
endocarditis recurrence and death.
Results. We identified a significant association between PICC line misuse and infective
endocarditis recurrence (OR=2.62, P=0.005). In addition, survival analyses showed that
PICC line misuse increased both the rate of infective endocarditis recurrence (SHR=2.60,
P=0.001) and mortality (HR=3.00, P=0.01).
Conclusion. PICC line misuse was associated with infective endocarditis recurrence and
mortality. Preventative health interventions to target this high-risk group of patients need to
be developed.

Keywords
Infective endocarditis; injection drug use; persons who inject drugs; recurrent endocarditis;
competing risks
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Summary for Lay Audience
Infective endocarditis is a potentially fatal infectious disease that damages the chambers and
structural integrity of the heart. The use of injection drugs has become a significant
contributing factor for the occurrence and recurrence of infective endocarditis. Previous
studies have demonstrated that infective endocarditis is responsible for mortality rates of up
to 40% and recurrence rates of up to 32% among the population of people who inject drugs
(PWID). Treatment of infective endocarditis often involves cardiac surgery to replace
damaged cardiac valves. However, this form of treatment is problematic among PWID due to
high infective endocarditis recurrence rates and lethality of recurrent infection of prosthetic
valves. Current knowledge is limited regarding the recurrence of infective endocarditis
among PWID. Therefore, it is important to further the understanding of the risk factors
associated with the recurrence of infective endocarditis to help guide informed decisionmaking regarding cardiac surgery among PWID. A challenge faced when assessing key
factors that influence the recurrence of infective endocarditis is the presence of competing
risks, which impede the recurrence of infective endocarditis and may lead to false inferences
regarding the overall survival of PWID. This thesis used data from electronic medical records
from St. Joseph's Hospital and London Health Sciences Center to characterize risk factors
that are associated with the recurrence of infective endocarditis, assess the probability of
infective endocarditis recurrence with consideration for death as a competing risk, and
evaluate the association between survival time and important risk factors among PWID.
Through analysis of endocarditis recurrence, this thesis identified peripherally inserted
central catheter line misuse as an important risk factor for increased (1) odds of the
development of recurrence of infective endocarditis, (2) rate of infective endocarditis
recurrence, and (3) risk of mortality among PWID. Furthermore, this thesis identified
admission to the intensive care unit and cardiac surgery as additional risk factors for
increased risk of mortality among PWID. The results of this thesis will have a significant
impact on public health efforts in the prevention of infective endocarditis recurrence and aid
clinicians in targeting prevention strategies towards patients who have misused their
peripherally inserted central catheter.
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Chapter 1

1

Introduction

This chapter introduces the topic, objectives, and structure of the thesis. Section 1.1
provides an overview of the thesis topic. The objectives of the thesis are then outlined in
Section 1.2. Section 1.3 discusses the role of the student. Lastly, Section 1.4 summarizes
the structure of the thesis.

1.1 Overview of thesis topic
As a consequence of the rising opioid and stimulant epidemic, the incidence of infectious
blood-borne diseases has significantly increased among the population of PWID.1
Common blood-borne diseases seen among PWID include human immunodeficiency
virus (HIV), and hepatitis B and C viruses.1 Furthermore, the incidence of bacterial heart
infections, such as infective endocarditis (henceforth referred to as endocarditis), have
been gradually increasing among this marginalized, high-risk population.1
Endocarditis is a type of heart inflammation that affects the endocardium (inner surface)
of the heart valves and chambers.2 Endocarditis infection is separated into three types,
left-sided, right-sided, and bilateral infection, each affecting their corresponding cardiac
structures. Left-sided endocarditis is commonly found in the population of non-PWID
(individuals who do not inject drugs), whereas right-sided infection is common in the
population of PWID. Endocarditis is a considerable cause of morbidity and mortality in
developed countries, with mortality rates of 25% among the general population and up to
40% among the population of PWID.3–5 Injection drug use (IDU) is considered a
predominant risk factor for endocarditis due to the use of contaminated injection
equipment and the injection of nonsterile substances.
Recurrence of endocarditis infection is defined in literature as a repeated episode that
either occurs more than six months from the previous episode or is caused by a different
causative organism.6–8 Among the general population, endocarditis recurrence has been
found to be associated with increasing age,9,10, male sex,9 prior heart disease,6,11 presence
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of prosthetic devices,9,12 and previous endocarditis episodes.13 Conversely, risk factors
for recurrence of endocarditis differ among the population of PWID. Continued drug
use,11,14 location of infection,14 bacteremia,7 and misuse of peripherally inserted central
catheter (PICC) lines7 have been found to significantly increase the probability of
endocarditis recurrence among the population of PWID.

1.2 Thesis objectives
There is limited literature on the recurrence of endocarditis among the population of
PWID, specifically. To date, no study has assessed the probability of endocarditis
recurrence specifically among the population of PWID with consideration for the effects
of death as a competing risk. This thesis aimed to build on existing literature by
addressing this knowledge gap. A retrospective cohort study using the world’s largest
detailed population-based dataset of PWID and endocarditis was conducted to address the
following research objectives:
Research Objective 1. Characterize important factors that contribute to the recurrence of
endocarditis among PWID in London, Ontario
Research Objective 2. Assess the probability of disease recurrence in the presence of
competing risks among PWID in London, Ontario
Research Objective 3. Evaluate the associations of survival time and predictor variables
among PWID in London, Ontario

1.3 Role of the student
Data collection was conducted by Dr. Michael Silverman and St. Joseph's Health Care
London and provided to the student for use in this thesis manuscript. The objectives and
research questions were formulated by the student in conjunction with co-supervisors,
Drs. Michael Silverman, and Tara Elton-Marshall. The thesis advisory committee,
consisting of co-supervisors and Dr. Yayuan Zhu, provided input on thesis methodology.
The student’s thesis committee provided regular consultation and guidance throughout
the completion of the study.
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1.4 Thesis structure
This thesis manuscript is comprised of five chapters and five appendices. Chapter 2
provides information on the current knowledge of endocarditis recurrence. Chapter 3
outlines the data source, study population and setting, measures and outcome variables,
missing data and statistical methods used to address the study objectives and research
questions. Chapter 4 presents the study findings for each defined objective. Finally,
Chapter 5 discusses the implications of the study findings, strengths and limitations, and
future directions.
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Chapter 2

2

Literature review

There is limited literature that describes the recurrence of endocarditis among PWID.
This chapter aims to outline current evidence regarding endocarditis and PWID to
ascertain the plausibility of this thesis. Section 2.1 defines endocarditis, its
pathophysiology, diagnosis and treatment, and associated risk factors. Section 2.2
provides the epidemiology of PWID worldwide, in Canada and in Ontario. Section 2.3
compares the clinical characteristics of endocarditis among PWID and non-PWID.
Section 2.3 also defines recurrent endocarditis and provides evidence on the factors
associated with its recurrence. Section 2.4 addresses current gaps in the literature and
how this thesis will contribute to the field of knowledge. Section 2.5 briefly describes
competing risks and Section 2.6 provides context of the current study, its setting, and
population demographics.

2.1 Endocarditis
Endocarditis is a cardiovascular disease and a consequence of bacteremia.15 Endocarditis
can be classified as either acute, subacute or chronic.16 Acute endocarditis is defined by
rapid clinical presentation and life-threatening disease progression.16 Conversely,
subacute and chronic infections are less dire and have indistinct clinical presentation.16
Endocarditis can result from numerous types of bacteria; common microorganisms
include (1) streptococci: Viridans streptococci, (2) staphylococci: Staphylococcus aureus
including methicillin resistant strains (MRSA), (3) enterococci, and (4) HACEK:
Haemophilus parainfluenza, Haemophilus aphrophilus, Actinobacillus (Haemophilus)
actinomycetemcomitans, Cardiobacterium hominis, the Eikenella species, and the
Kingella species (5) gram negative rods including pseudomonas, and (6) fungi.17
Streptococci and staphylococci are responsible for the majority of endocarditis cases;
streptococci account for between 50% and 80% of all endocarditis cases in non-PWID
and staphylococci account for 50% of acute endocarditis cases, and 20% and 30% of
subacute endocarditis cases.15,17 In PWID, staphylococci may account for 70% or more
cases and fungi are also more common.3
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Endocarditis occurs when the endocardial layer (endocardium) of the heart is damaged,
resulting in inflammation and the release of thromboplastin, a blood coagulation tissue
factor.18,19 The endocardium covers the heart’s inner lumen—chambers—and is
composed of a layer of endothelial cells.20,21 Endocarditis consists of a multistage process
called vegetation formation that occurs on the surface of the heart’s valve line of
closure.18 This process begins when the bacteria spreading hematogenously bind to the
damaged endocardium.19 Once attached, thromboplastin stimulates the accumulation of
platelets and fibrin—cells and protein used in blood coagulating mechanisms,
respectively—at the site of injury, which sheathe the bacteria, forming a “vegetation”,
illustrated in Figure 2.1. If left untreated, the vegetation can further damage the heart
valves and result in congestive heart failure or the need for prosthetic valve
replacement.19 Endocarditis can affect native valves, prosthetic valves or intracardiac
devices.22

Figure 2.1 Infective endocarditis of the mitral valve
Source: Mayo Foundation For Medical Education And Research – Endocarditis.23 Used with permission of
Mayo Foundation for Medical Education and Research, all rights reserved. (See Appendix A for letter of
permission)
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There are three types of native valve endocarditis: left-sided, right-sided and bilateral
infection. Left-sided endocarditis is the most common type of infection and affects the
mitral valve and the aortic valve.17 Conversely, right-sided endocarditis is common
among PWID and patients with cardiac devices, and accounts for 5% to 10% of all
endocarditis infections.24 Studies have demonstrated that patients with right-sided
endocarditis tend to be younger and have less comorbidities.18 Vegetation formation of
right-sided endocarditis affects the tricuspid valve with rare involvement of the
pulmonary valve.17
Prosthetic valve endocarditis is defined by infection of parts of a prosthetic heart valve.25
Prosthetic valve endocarditis is a complication of valve replacement; bacteria are
introduced during surgical intervention or subsequently postoperatively via
hematogenous dissemination in hospital (nosocomial) or in the community.25 The risk of
nosocomial-acquired prosthetic valve endocarditis is estimated to be 5% higher in
patients who receive surgical intervention during an active case of endocarditis.25

2.1.1

Diagnosis and treatment

Endocarditis is a complex disease with a variety of symptoms. Patients with endocarditis
may experience the following conventional symptoms:
•

Constitutional symptoms: fever, weight loss, anorexia, arthralgia, night sweats
and/or rigors.17

•

Cardiac phenomena: development of heart murmur and/or worsening of current
heart murmur.17

•

Skin lesions: Osler nodes on fingers or toes, Janeway lesions on palms of hand or
soles of feet, embolic or vascular petechiae, and/or clubbing.

•

Eye hemorrhages: Roth spots and/or conjunctival hemorrhages.17

•

Splenic phenomena: splenic infarction.17

•

Neurological phenomena: cerebral emboli, acute confusion and/or mycotic
aneurysms.17

•

Renal phenomena: renal infarction and/or glomerulonephritis.17
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Diagnosis of endocarditis can be difficult and requires a combination of signs, symptoms,
clinical suspicion and diagnostic tests.15 The modified Duke Criteria were developed to
provide healthcare professionals with a formal endocarditis diagnosis through a series of
major and minor criteria, shown in Table 2.1.17 Suspected patients are stratified into three
classifications based on the criteria they fulfill:15,17,26
•

Definite endocarditis: either (1) pathologically proven endocarditis, or (2)
fulfillment of either (i) two major criteria, (ii) one major and three minor criteria,
or (iii) five minor criteria.15,26

•

Possible endocarditis: fulfillment of either (i) one major and one minor criterion
or (ii) three minor criteria.15,26

•

Rejected: either (1) firm alternative diagnosis, (2) resolution of endocarditis
syndrome with antibiotic treatment for ≤ 4 days, or (3) no pathologic evidence of
endocarditis at surgery or autopsy, with antibiotic treatment for ≤ 4 days.15,26
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Table 2.1 Duke Criteria for the Diagnosis of Endocarditis17,26
Major Criteria

Minor Criteria

(1) Positive blood culture for endocarditis

(1) Predisposition: predisposing heart condition or intravenous drug
use

A. Typical microorganism consistent with endocarditis from two separate blood
cultures as noted below:
a

i. viridans streptococci, Streptococcus bovis , or HACEK group; or
ii. community-acquired Staphylococcus aureus or enterococci, in the
absence of a primary focus; or
B. Microorganisms consistent with endocarditis from persistently positive
blood cultures defined as:
i. at least two positive cultures of blood samples drawn > 12 hours apart
or
ii. all of three or a majority of four or more separate cultures of blood
(with first and last sample drawn at least 1 hour apart).
(2) Evidence of endocardial involvement

(2) Fever: temperature ≥ 38.0˚C
(3) Vascular phenomena: major arterial emboli, septic pulmonary
infarct, mycotic aneurysm, intracranial hemorrhage, conjunctival
hemorrhages and Janeway’s lesions
(4) Immunologic phenomena: glomerulonephritis, Osler’s nodes,
Roth’s spots, and rheumatoid factor
(5) Microbiological evidence: positive blood culture but does not
meet a major criterion as noted aboveb or serological evidence of
active infection with organism consistent with endocarditis
(6) Echocardiographic findings: consistent with endocarditis but do
not meet a major criterion as noted above

A. Positive echocardiogram for endocarditis defined as:
i. oscillating intracardiac mass on valve or supporting structures, in the
path of regurgitant jets, or on implanted material in the absence of an
alternative anatomic explanation, or
ii. abscess, or
iii. new partial dehiscence of prosthetic valve
B. New valvular regurgitation (worsening or changing of pre-existing murmur
not sufficient)
Abbreviations: HACEK, Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella species, and Kingella kingae
a
Includes nutritionally variant strains (Abiotrophia species)
b
Excludes single positive cultures for coagulase-negative staphylococci and organisms that do not cause endocarditis
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Treatment of endocarditis is dependent on the complexity of the disease. Antibiotic
therapy is used for all cases, and is used alone when the structural integrity of the cardiac
valves is maintained; approximately 50% of endocarditis cases are treated with antibiotic
therapy alone.16,27 Conversely, surgical intervention is required if infection severely
damages the integrity of the cardiac valves leading to heart failure, or if infection cannot
be controlled with antibiotics alone or if recurrent emboli occur despite antibiotic
therapy.27

2.1.2

Risk factors

Current literature demonstrates several factors that increase the risk of developing
endocarditis. Cardiac structural abnormalities (rheumatic heart disease and congenital
heart disease),15,16,28 prosthetic material (cardiac devices or prosthetic valves),15,28
invasive medical procedures,16 HIV and IDU16,28 have been identified in literature as
primary risk factors for endocarditis and will be further explored in Section 2.3.1.

2.1.3

Epidemiology of endocarditis

Endocarditis is life-threatening and a significant cause of morbidity and mortality in
developed countries, resulting in a mortality rate of 25%.3,5 Literature suggests that the
general incidence of endocarditis is stable; incidence of endocarditis is estimated to be
between 3 and 7.5 episodes per 100,000 person-years.3,29 Despite the overall stability of
the incidence of endocarditis, it is steadily increasing among PWID, resulting in mortality
rates of up to 40%.3,4 As a result, IDU is considered a predominant risk factor for the
disease.30 The incidence of endocarditis is considerably higher among PWID compared to
those who do not use injection drugs.31
The use of prescription opioids has become an important public health concern and
contributes to the growing rates of substance use disorders in Canada.32 Non-medical use
of prescription opioids can be administered through injection, swallowing or snorting.33
Opioid medication is often used to treat pain and can cause a sense of euphoria, making
these types of medication highly addictive.34–36 Opioids are classified into three distinct
categories: natural, semi-synthetic and synthetic.37 Natural opioids are directly derived
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from the opium poppy and include codeine, morphine and thebaine.37,38 Semi-synthetic
opioids, including hydromorphone, heroin and oxycodone, are chemically manufactured
using natural opiates.38,39 Lastly, synthetic opioids are completely chemically
manufactured and include methadone and fentanyl.38,39 The opioid crisis is attributable to
increasing rates of opioid prescribing by healthcare professionals and the development of
synthetic opioids.35,40
Evidence suggests the non-medical use of prescription opioids is a contributing factor to
the use of more potent injection opioids, such as heroin.33,41 Literature theorizes that the
transition of prescription opioids to heroin is a multistep process,42 demonstrated in
Figure 2.2. The first step in the theorized process is the ease of drug accessibility.42
Access to prescription opioids can result from one’s own prescription or a family
member’s or friend’s prescription.43 Prolonged misuse of prescription opioids results in
drug dependence.42 Drug dependence alters the function of neurons by decreasing their
ability to release noradrenaline, a neurotransmitter responsible for stimulating alertness.44
Consequently, the neurons adapt to the presence of the opioid by increasing their activity,
resulting in withdrawal symptoms such as anxiety, jitters and muscle cramps in the
absence of the opioid.44 Although repeated use of the opioid suppresses these symptoms,
it can also lead to opioid tolerance.37 Opioid tolerance occurs when the drug user no
longer responds to the opioid stimulus.44 Thus, opioid drug users will either (1) need to
increase the amount and frequency of the drug to obtain the desired effect or (2)
transition to a more potent drug.33,37

Access to opioid
medication

Opioid
dependence

Opioid tolerance

Increased dose or
drug transition

Figure 2.2 Theory behind the transition from prescription-opioid use to injection
drug use
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Lankenau et al.43 conducted an exploratory qualitative study to understand the patterns of
prescription opioid misuse initiation among young PWID. Results from their study
demonstrated 86% of their study sample (43/50) misused prescription opioids prior to
transitioning to heroin.43 Similar patterns of transition in Figure 2.2 were observed among
sample participants who injected prescription opioids prior to heroin. Furthermore, the
transition from prescription opioid misuse to injection opioid use can also be attributable
to supply reduction efforts, which aim to address the opioid crisis.45 Electronic
prescription drug monitoring programs are a type of supply reduction strategy that gather
information on the proportion of prescriptions dispensed, limiting the availability of
prescription opioids and therefore increasing their price.45,46 Consequently, drug users
who are dependent on these drugs will need to either find more money to pay for the
limited resources or find a less expensive option, such as heroin.45
In addition to the opioid epidemic, the use of stimulants is an increasing public health
concern among PWID.47 Non-medical use of prescription stimulants can be administered
through injection of dissolved powder, smoking, snorting, or swallowing the drug in pill
form.48 Prescription stimulants are often used to increase the levels of dopamine and
norepinephrine in the brain which increases overall brain activity.48 Crystal
methamphetamine, familiarly known as crystal meth, is an extremely powerful and
addictive stimulant.49 Similar to prescription opioid misuse, prescription stimulant misuse
has the potential to lead to serious substance use disorders.48,49 The transition from
prescription stimulant use to crystal meth follows a similar multistep process as seen in
Figure 2.2. Misuse of prescription stimulants can lead to drug dependence which
prolongs the use of the stimulant. Furthermore, long-term drug misuse leads to drug
tolerance, whereby stimulant drug users either (1) need to increase the amount and
frequency of the drug to obtain the desired effect or (2) transition to a more potent drug,
such as crystal meth.48
The misuse of prescription opioids and stimulants is a global public health concern and is
increasing among PWID. Furthermore, the use of injection opioids and stimulants
increases the risk of transmission of blood-borne diseases, such as endocarditis, due to
the use of contaminated injection paraphernalia.4,49,50 However, a systematic review by
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Serhan and Silverman51 demonstrates that despite the rise in IDU-related endocarditis,
current evidence does not suggest the type of drug injected has a significant impact on the
development of endocarditis.

2.2 Injection drug use
IDU is a major public health concern that contributes significantly to worldwide mortality
and morbidity.52 Moreover, IDU has high health, economic and social burdens. Harm
reduction programs have been established to help reduce the burden of IDU.53 Literature
demonstrates that needle exchange and recovery programs (NEP) are associated with a
decrease in sharing needles and injection equipment, and risky behaviour.53–56 A study
conducted by Bailey et al.55 found frequent users of NEPs (≥ 7 visits) were less likely to
share their needles (odds ratio [OR] = 0.32, 95% confidence interval [CI] 0.19 to 0.54) or
injection paraphernalia (OR = 0.51, 95% CI 0.30 to 0.85) with other users, or reuse their
own equipment (OR = 0.25, 95% CI 0.13 to 0.45) than those who visited NEPs less often
(1 to 6 visits), adjusting for age, gender, ethnicity, recruitment method, duration and
frequency of injection use. Similarly, a study by Gibson et al.56 observed a significant
decrease in the probability of reuse of unsterile needles (17% of NEP users versus 35% of
non-NEP users, P = 0.003), needle sharing (27% of NEP users versus 50% of non-NEP
users, P = 0.001) and high risk behaviour (12% of NEP users versus 24% of non-NEP
users, P = 0.03) among NEP users compared to non-NEP users.
The World Health Organization57 assessed the evidence of the efficacy of NEPs in
preventing blood-borne diseases, such as HIV. Evidence demonstrates a positive impact
on injection practices among PWID.57 However, despite the strength of the evidence
provided, the report draws attention to the limitations of the studies.57 From their review,
the World Health Organization57 identified dichotomous classifications of NEP users and
non-NEP users, which may confound and overestimate the probability of needle sharing
and reuse among non-NEP users. Non-NEP users may only use sterile injection
equipment that have been acquired from sources other than NEPs.57 Furthermore, these
studies rely on self-reported data, which can be affected by a number biases that
underestimate the protective effect of NEPs.57 In addition, a systematic review by
Fernandes et al.58 found many studies assessing the effectiveness of NEPs were at
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moderate to high risk of bias. The quality of evidence was assessed using the Risk of Bias
In Systematic Reviews tool, which assesses risk of bias among eligibility criteria,
selection of studies, data collection, appraisal, synthesis and findings.58 The results of this
systematic review conclude that further high quality studies are required to adequately
address the impact of NEPs on IDU.58
PWID account for approximately 0.7% of the Canadian population, many of which face
several barriers to care.7,52 IDU is heavily stigmatized, which significantly impacts the
wellbeing and quality of life of PWID.59 As a result, PWID often face discrimination and
may feel discouraged to access adequate healthcare or services aimed to reduce harm
caused by IDU.60,61 Additionally, access to harm reduction services may be limited or
inaccessible.62 Therefore, PWID tend to employ self-initiated harm reduction strategies;
rubbing alcohol, soap or hand sanitizer may be used to clean injection equipment.62
However, these strategies are not always employed.62 Consequently, PWID are at a
higher risk of developing blood-borne diseases, such as HIV, hepatitis C and
endocarditis.

2.2.1

Epidemiology of injection drug use

In 2015, it was estimated that there was approximately 15.6 million PWID worldwide,
which accounted for 0.33% (95% uncertainty interval [UI] 0.21 to 0.49) of individuals
aged 15 to 64 years.63 A systematic review by Degenhardt et al.63 found Southeast Asia
(4.0 million, 95% UI 3.0 to 5.0 million), eastern Europe (3.0 million, 95% UI 1.7 to 5.0
million) and North America (2.6 million, 95% UI 1.5 to 4.4 million) have the largest
proportions of PWID. The prevalence of IDU varies across countries, resulting in
prevalence rates ranging from 0.01% to 4.19%,64 illustrated in Figure 2.3. In addition,
Degenhardt et al.63 found illicit injection drug use is more common among men than
women (79.6% versus 20.4%, globally).63 In Canada, the prevalence of IDU ranges from
1.04% to 1.40%.64
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Figure 2.3 Estimated prevalence of injection drug use by country
Source: © 2017 Louisa Degenhardt, Amy Peacock, Samantha Colledge, et al. Published by Elsevier Ltd.
DOI:https://doi.org/10.1016/S2214-109X(17)30375-3; Abbreviations: IDU, injecting drug use.

2.3 Endocarditis and injection drug use
Literature suggests approximately 5% to 20% of PWID will experience an episode of
endocarditis.65 A study conducted by Wurcel et al.65 observed a substantial change in the
overall proportion of IDU-related endocarditis hospitalizations in the United States
between 2000 and 2013, resulting in an increase from 7% in 2000 to 12.1% in 2013.

2.3.1
2.3.1.1

Clinical characteristics of patients with endocarditis
Age, ethnicity and sex

Patient characteristics differ significantly among PWID and non-PWID with endocarditis.
Demographic analyses regarding PWID and non-PWID show differences in sex, ethnicity
and age. Among both non-PWID and PWID, endocarditis is more frequently observed
among male patients than female patients, resulting in a 2:1 ratio.6,9,16,65–67 In addition, the
majority of endocarditis patients are Caucasian.65,68 Among non-PWID, evidence
suggests that the incidence of endocarditis increases with age.10 In the 1980s, the mean
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age of patients with endocarditis was observed to be between 44 and 46 years.22
However, as a consequence of medical advancement, the decreased incidence of
rheumatic heart disease and increased incidence of degenerative valve heart diseases, the
observed mean age of non-PWID with endocarditis rose dramatically and increased to
greater than 70 years.22,69 Furthermore, literature suggests the risk of endocarditis among
elderly patients (greater than 65 years of age) is 4.6 times higher than the general
population.70 In contrast to the general population, PWID with endocarditis are younger.
A study conducted by Rodger et al.3 reported a median (interquartile range [IQR]) age of
34 (28 to 42) years among PWID with endocarditis. Furthermore, studies conducted on
the general population reported mean and median aged PWID between 20 and 40.8
years.4,11,14,30,66–68,71

2.3.1.2

Cardiac structural abnormalities

Approximately 75% of patients who suffer from endocarditis have accompanying heart
diseases.16 Rheumatic heart disease and congenital heart disease cause lesions and
scarring of the endothelial layer of the heart valves, which contributes to the onset of
endocarditis.72 Prior to the development of antibiotics, rheumatic heart disease was the
primary risk factor for development of endocarditis.22 However, as a consequence of
medical advancement, the prevalence of rheumatic heart disease has decreased in
developed countries, but remains a public health concern among patients in developing
countries who have limited access to adequate healthcare services and consequently
antibiotics.22,73 As a result, the significance of rheumatic heart disease as a risk factor for
endocarditis in developed countries has decreased.69,72 However, congenital heart disease
continues to be an important predisposing factor in the development of endocarditis.15,74
Studies have shown that predisposing heart diseases are more frequently associated with
non-IDU related endocarditis compared to IDU-related endocarditis.30,75 Kadri et al.75
found that PWID were significantly less likely to have congenital heart disease compared
to non-PWID (9.1% versus 21.9%, P < 0.001). Similar results were found in a study by
Rudasill et al.30 (8.1% versus 15.5%, P < 0.001).
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2.3.1.3

Invasive medical procedures

Bacteremia can also result from exposure to invasive medical and surgical procedures.76
As previously mentioned, bacteremia triggers endocarditis development. The increased
risk of bacteremia from invasive medical and surgical procedures can also predispose
patients to endocarditis. Approximately 25% of endocarditis cases occur after medical
exposure.76 A study conducted by Janszky et al.76 found invasive outpatient procedures,
such as bone marrow puncture (relative risk/risk ratio [RR] = 4.33, 95% CI 1.24 to
15.21), bronchoscopy (RR = 5.00, 95% CI 1.10 to 22.82), dialysis (RR = 4.33, 95% CI
2.10 to 8.95), coronary angiography (RR = 4.75, 95% CI 1.61 to 13.96) and blood
transfusions (RR = 5.50, 95% CI 1.22 to 24.80) are associated with a four to 5.5-fold
increase in the relative risk of endocarditis.

2.3.1.4

Prosthetic valves

Prosthetic devices, such as prosthetic heart valves, predispose patients to infection.
Infection occurs when bacteria colonized on the surface of the skin enter the host when a
prosthetic device is implanted.77 A challenge of treating prosthetic device infection is the
presence of a biofilm on the surface of the device.77 A biofilm is composed of invasive
bacteria and a matrix of adherent lipids, nucleic acids, polysaccharides and protein that
protect the bacteria from the host’s immune response.77
Surgery frequently occurs among patients infected by resistant and/or virulent
microorganisms.78 Evidence demonstrates that surgical intervention has resulted in
positive outcomes for non-PWID with endocarditis.3,79–84 However, clinicians are faced
with difficulties when considering surgery for PWID as recurrent endocarditis and
reoperation are frequent.3,85 As a result, prosthetic valve endocarditis is mostly observed
among non-PWID. A study by Wang et al.86 found that compared to native valve
endocarditis, prosthetic valve endocarditis was significantly associated with older age
(65.0 versus 56.3 years, P < 0.001) and negatively associated with IDU (1.8% prosthetic
valve endocarditis versus 12.4% native valve endocarditis, P < 0.001).
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2.3.1.5

Human immunodeficiency virus

Globally, HIV affects approximately 2.8 million (95% UI 1.5 to 4.5 million) PWID,
which accounts for 17.8% (95% UI 10.8% to 24.8%) of the PWID global population.63
Figure 2.4 demonstrates an estimated global prevalence of HIV among PWID. From their
systematic review, Degenhardt et al.63 estimated large prevalence of HIV among PWID
in eastern Europe (24.7%, 95% UI 15.6% to 33.9%) and Latin America (35.7%, 95% UI
15.0% to 56.6%), demonstrated in Figure 2.4. In comparison, estimates of prevalence
rates of HIV among Canadian PWID were much lower (11.3%, 95% UI 8.5% to 14.2%)
(Figure 2.4).64

Figure 2.4 Estimated HIV prevalence among people who inject drugs by country
Source: © 2017 Louisa Degenhardt, Amy Peacock, Samantha Colledge, et al. Published by Elsevier Ltd.
DOI:https://doi.org/10.1016/S2214-109X(17)30375-3; Abbreviations: IDU, injection drug use. No eligible
report=evidence of IDU located, but no study of HIV prevalence among people who inject drugs that met
our eligibility criteria was located.

Ontario had the highest proportion of HIV incident cases in Canada (39.2%) in 2018,
followed by Quebec (29.9%).87 The majority of Canadians living with HIV were found to
be between the ages 30 and 39 years (30.4%) with a diagnosis rate of 15.4 per 100,000
Canadians.87 The 20 to 29 and ≥ 50 age groups were found to have the second largest
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proportion of Canadians living with HIV (22.5%).87 The diagnosis rate among the 20 to
29 year age group was the second highest, resulting in a rate of 11.5 cases per 100,000,
which is similar to that of the 40 to 49 year age group.87 Of all reported HIV cases in
2018, male Canadians accounted for 70.7%.87 Among both male and female Canadians
living with HIV, the highest proportion of cases belonged to the 30 to 39 year age group
(28.9% versus 34.3%, respectively). IDU was documented as the third most frequently
reported HIV exposure category in 2018. The incidence rate of HIV via IDU increased
from 16.2% in 2017 to 18.3% in 2018.87 The risk of acquiring HIV was 22 times higher
in PWID than the general population.88 HIV is common among PWID; the Centers for
Disease Control and Prevention89 reports one in 10 injection drug users will acquire HIV.
Literature suggests patients living with HIV have a 40% to 75% increased risk of
cardiovascular disease.90,91 Evidence shows HIV infection increases a patient’s relative
risk of myocardial infarction and coronary heart disease by 1.5 to two-fold.90 Moreover, it
is suggested that HIV infection is also associated with endothelial cell dysfunction,92
predisposing patients to endocarditis.
Coinfection of endocarditis and HIV occurs frequently in PWID.93,94 In a study
comparing IDU-related and non-IDU related endocarditis, researchers observed that
PWID were more likely to be affected by HIV (6% versus 1.2%, P < 0.001).75
Furthermore, the immunosuppression caused by HIV infection increases a patient’s risk
of developing endocarditis.93,94 A study conducted by Gebo et al.93 found patients with
lower CD4 counts (less than 50 cells/mm3), indicating greater immunosuppression, were
at higher risk of developing endocarditis compared to patients with higher CD4 counts.
Multivariate analyses demonstrated a decrease in odds of developing endocarditis per
increase in CD4 cell count.93 Similar results were found in a 1996 nested case-control
study by Manoff and colleagues.95 In addition, Gebo et al.93 found no association between
the use of highly active antiretroviral therapy and the development of endocarditis (OR =
0.71, 95% CI 0.38 to 1.37). Furthermore, the association between mortality due to
endocarditis and HIV status was not statistically significant.96
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2.3.1.6

Causative organisms

There are many organisms that can cause endocarditis. Streptococci and staphylococci
species account for 80% of endocarditis cases.15 The increase of healthcare acquired
endocarditis has also increased the prevalence of Staphylococcus aureus and coagulasenegative staphylococci related endocarditis cases.15 In addition, the presence of
enterococci has increased and has also been found to be associated with healthcare
acquired endocarditis.15 The increase in staphylococci bacteremia in turn decreases the
proportion of endocarditis cases attributable to viridans group streptococci.15 Causative
organisms vary by region.15 In North America, Staphylococcus aureus, streptococci and
enterococci are responsible for 43%, 17% and 13% of endocarditis cases, respectively.15
Conversely, these numbers differ dramatically in South America. Among endocarditis
cases in South America, Staphylococcus aureus, streptococci and enterococci are
responsible for 17%, 39% and 20% of endocarditis cases, respectively.15 Rheumatic heart
disease resulting from untreated beta-haemolytic streptococcal throat infection is more
predominant in South America than North America,97 resulting in a higher proportion of
endocarditis cases caused by viridans streptococci.
Welton et al.11 observed that Staphylococcus aureus was the most prevalent causative
organism for overall endocarditis cases (59%), followed by viridans group streptococci
(16%) and Enterococcus fecalis (9%). In addition, these causative organisms vary by
IDU and non-IDU associated endocarditis. Staphylococcus aureus is a predominant
causative organism found among both IDU- and non-IDU related endocarditis,16
however, its prevalence is greater among IDU-related endocarditis. Among PWID, the
prevalence of Staphylococcus aureus has been observed to be between 30.6% and
77.8%.3,7,30,66,75,93 Conversely, among non-PWID, the prevalence of Staphylococcus
aureus has been observed to be between 19.1% and 22.1%.30,75 Furthermore,
streptococcus bacteremia has also been demonstrated to contribute to IDU and non-IDU
related endocarditis; prevalence ranges from 4.4% to 13% among PWID and 7% and
15.8% in non-PWID.3,7,30,66,75,93
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2.3.1.7

Location of infection

As previously stated, left-sided endocarditis affects the mitral and aortic valves, rightsided endocarditis affects the tricuspid and pulmonic valves, and bilateral endocarditis
affects structures on both the left- and right-side of the heart.7,17 Right-sided endocarditis
is commonly observed among PWID,24 thus, the tricuspid valve is the primary location of
vegetation. Rodger et al.3 found 58.4% of IDU-related endocarditis cases had vegetation
of the tricuspid valve, followed by the aortic (12.9%) and mitral valves (11.9%). In a
subsequent study, Rodger et al.7 found similar vegetation trends; the tricuspid valve was
affected in 62.7% of IDU-related endocarditis cases, followed by the aortic and mitral
valves (15.6% each). Moreover, Ortiz-Bautista and colleagues24 also observed a large
proportion of tricuspid valve vegetation (58%) among PWID.

2.3.2
2.3.2.1

Recurrence of endocarditis
Search strategy and inclusion criteria

To gain better understanding of the current evidence of recurrent endocarditis among the
population of PWID, specifically, a systematic review was conducted by searching
MEDLINE (Ovid), EMBASE and Web of Science databases on July 27, 2020. For
recurrent endocarditis, each database was searched using the following terms: repeat
endocarditis OR repeat infective endocarditis OR repeat infectious endocarditis OR
recurrent endocarditis OR recurrent infective endocarditis OR recurrent infectious
endocarditis. Next, to find literature on injection drug use, each database was searched
using the following terms: injection drug user* OR intravenous drug user* OR IDU* OR
drug user* OR persons who inject drugs OR people who inject drugs OR PWID OR
injector* OR drug injector* OR injecting drug user* OR injecting drug abuse* OR
injection drug user* OR injection drug abuse* OR drug utilization or intravenous
substance abuse* OR intravenous substance user*. Individual searches were conducted
for recurrent endocarditis and injection drug use. Results were combined using the AND
logical operator. A detailed outline of the search strategy can be found in Appendix C.
This search strategy returned 42 results which were exported into Mendeley. Of these
results, 17 duplicates were removed. The title and abstract of the remaining 25 records
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were screened and individual case reports and studies in which the primary focus was not
recurrent endocarditis or PWID were removed. Full text screening of the remaining three
articles was conducted; an editorial comment was excluded. This left two studies for
analysis (n = 2), shown in Table 2.2. The review process is illustrated in the Preferred
Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram98 in
Figure 2.5.
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Table 2.2 Summary of literature regarding recurrent endocarditis among PWID
Authors, date
of publication

Setting

Patient population

Huang, Barnes

Winston-

PWID ≥ 18 years diagnosed with

& Peacock

Salem, North

endocarditis who were admitted to

Carolina,

the Wake Forest Baptist Medical

United States

Center between January 2004 and

2018

14

Study sample size
94

Study objective(s)
•

Report clinical and demographic characteristics,
and outcomes of repeat endocarditis among PWID

•

Determine the clinical factors that predispose
PWID to recurrent endocarditis

January 2017.

Rodger et al.

London,

PWID ≥ 18 years diagnosed with

20197

Ontario,

definite endocarditis admitted to

Canada

any of the three acute care centers
in London, Ontario between
February 2007 and March 2016

212

•

Characterize recurrent endocarditis among PWID

IDENTIFICATION
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Records identified through database
searching
(n = 42)

INCLUDED

ELIGIBILITY

SCREENING

Records after duplicates removed
(n = 25)

Records screened
(n = 25)

Records excluded
(n = 22)

Full-text articles accessed for
eligibility
(n = 3)

Full-text articles excluded,
with reasons
(n = 1)
•

Studies included in qualitative
synthesis
(n = 2)

Studies included in quantitative
synthesis
(n = 2)

Figure 2.5 PRISMA flow diagram

Editorial comment
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2.3.2.2

Defining recurrent endocarditis

Literature defines the recurrence of endocarditis as a repeated episode that either occurs
more than six months from the previous episode or is caused by a different causative
organism.6–8 It is estimated that repeated episodes of endocarditis occur in approximately
2% to 31% of patients.14 A study by Rodger et al.7 characterized recurrent endocarditis
among PWID. From their study, Rodger et al.7 observed a recurrence rate of 32.1%
among the PWID in their study sample, which is significantly greater than that of nonPWID (32.1% versus 6.2%, P < 0.001).7 Rodger et al.7 also found the median time to
recurrence (IQR) was 1.23 (0.33 to 2.86) years.

2.3.2.3

Risk factors for recurrent endocarditis among non-injection
drug users

The risk factors for recurrent endocarditis among non-PWID and PWID differs
significantly. Among the non-PWID population, recurrent endocarditis has been observed
to be associated with several risk factors:
Increasing age. Evidence demonstrates that the incidence of endocarditis increases with
age.10 Mansur et al.9 determined that patients’ age significantly increased the risk of
disease recurrence by 2% (RR = 1.02, P = 0.0003).
Sex/gender. Male sex was found to be significantly associated with increased risk of
disease recurrence (RR = 1.61, P = 0.023).9
Heart disease. Welton et al.11 found the proportion of prior heart disease (coronary heart
disease, rheumatic heart disease, prosthesis, and murmurs) increased two-fold in patients
with recurrent endocarditis episodes compared to those with single episodes (67% versus
38%, P < 0.05). Similarly, in a literature review by Baddour,6 prior heart disease was
commonly cited as a predisposing factor for recurrent episodes.
Prosthesis. As previously stated, prosthetic devices predispose patients to infection due to
the formation of a biofilm. Prosthetic valve endocarditis usually results from bacterial
interaction during surgery.99 Mansur et al.9 observed a 105% increase in the risk of
disease recurrence in the presence of prosthetic valves (RR = 2.05, P = 0.026). Similarly,
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Renzulli et al.12 determined prosthesis as a significant predisposing factor for recurrent
endocarditis (30.2% versus 9.4%, P = 0.001).

2.3.2.4

Risk factors for recurrent endocarditis among injection drug
users

IDU is a substantial predisposing factor for the development and recurrence of
endocarditis.6,11,14,100 An early study examining predisposing factors for recurrence of
endocarditis found PWID were at a significantly higher risk (P < 0.005) of developing
recurrent endocarditis within 12 months after their initial episode.11 Studies have
determined approximately 5.6% to 32.1% of PWID are likely to suffer from a recurrent
episode of endocarditis.7,14 PWID have distinct risk factors that contribute to its
recurrence:
Drug use. Recurrence of endocarditis is common among PWID primarily due to
continued use of injection drugs.66,101 Welton et al.11 observed drug recidivism in 78% of
patients with recurrent endocarditis episodes compared to patients with single episodes
(78% versus 50%, P < 0.05). Furthermore, a study by Huang et al.14 found increased
incidence of opioid injection drug use among patients who developed recurrent
endocarditis episodes (95.4% versus 67.7%, P = 0.01).
Location of infection. Vegetation of the tricuspid valve is common among PWID with
endocarditis and has been observed to be associated with disease recurrence (72.7%
versus 35.3%, P = 0.02).14 Furthermore, the odds of developing recurrent endocarditis is
increased nearly four-fold in the presence of echocardiographically visualized tricuspid
valve vegetation (OR = 3.8, 95% CI 1.2 to 11.9).14
Bacteremia. Rodger et al.7 found Staphylococcus aureus to be the leading causative
organism among both first and second endocarditis episodes in PWID (77.8% versus
63.2%). However, fungal endocarditis (typically caused by Candida spp.) significantly
increased among recurrent endocarditis episodes (7.4% versus 0.5%, P = 0.0005),7 which
aligns with previous literature.6,14,102 The increased proportion of Candida in recurrent
endocarditis episodes may be associated with preceding valvular damage.7 In addition,
the presence of fungal causative organisms in repeated endocarditis episodes was
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associated with a significant increase in the adjusted odds of mortality (OR = 16.49, 95%
CI 1.12 to 243.17, P = 0.04).7 Fungal endocarditis is frequently associated with IDU and
immunocompromised patients.102
Surgical intervention. Treatment of endocarditis among PWID is complex and clinicians
are faced with numerous challenges. Firstly, antibiotic resistant bacteria are common
among PWID, making it difficult to utilize antibiotic therapy, the primary treatment for
endocarditis.78 However, evidence suggests that surgical intervention increases the odds
of developing recurrent endocarditis five-fold (OR = 5.1, 95% CI 1.6 to 16.3) among
PWID.14 Moreover, PWID are at a higher risk of reinfection, resulting in increased risk of
mortality should operation of a prosthetic valve occur.78
PICC line misuse. PICC lines are used to administer intravenous treatments, such as
drugs, fluids or blood transfusions.103 Misuse of PICC lines to inject drugs other than
those used for treatment is a concern for patients identified as PWID.104 Rodger et al.7
observed a significant increase in the risk of recurrent endocarditis among PWID who
misused their PICC line (OR = 1.97, 95% CI 1.01 to 3.87, P = 0.04).
Referral to addictions services. It is posited that referring PWID to addiction services
may decrease the probability of recurrence of endocarditis. Study results from Rodger et
al.7 did not find a significant association between referral to addiction services and lower
risk of endocarditis recurrence (OR = 0.54, 95% CI 0.26 to 1.14, P = 0.11). However, this
finding may be the result of low statistical power as a small proportion (20.8%) of
patients were referred to addiction services during their first episode.7
Leaving against medical advice. Leaving against medical advice occurs when patients
decide to leave the hospital prior to finishing the recommended in-hospital treatment.105
This poses an increased risk in hospital readmission.105 The relationship between leaving
against medical advice and endocarditis recurrence was explored by Rodger et al.7 Study
findings suggest that leaving against medical advice was not significantly related to
recurrent endocarditis (OR = 0.50, 95% CI 0.21 to 1.20, P = 0.12).7 However, similar to
the results assessing the relationship between referral to addictions services and
endocarditis recurrence, this finding may be subjected to low statistical power as low
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proportions of patients left against medical advice among first (16.5%) and second
episodes (14.7%).7
ICU admission. It is hypothesized that admission to the ICU will result in worse patient
prognosis.
In addition, recurrent endocarditis is a consequence of the unique barriers to care that are
faced by PWID.7 Harm reduction practices, such as the use of NEPs, are not often used
especially in hospital and PWID are more likely to leave the hospital against medical
advice.7

2.4 Knowledge gaps
Review of the literature demonstrates limited knowledge regarding the recurrence of
endocarditis among injection drug use populations. To date, two studies have been
identified that focus on endocarditis specifically among injection drug users (Table 2.2).
Huang et al.14 conducted a retrospective cohort study on PWID aged ≥ 18 years from
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States of
America (n = 94). Patients were admitted to the center between January 2004 to January
2017.14 Among this patient cohort, a small sub-cohort of patients was identified as having
recurrent endocarditis cases within one year of the initial episode (n = 22).14 One-year
survival was significantly lower among PWID with recurrent endocarditis compared to
PWID with single-episode endocarditis (63.6% versus 95.4%, P < 0.01).14 In addition,
compared to PWID who experienced single-episode endocarditis, those who experienced
recurrent endocarditis frequently misused prescription opioids (95.5% versus 67.7%, P =
0.01), had increased visualization of tricuspid valve vegetations (72.7% versus 35.3%, P
= 0.02) and surgical intervention (59.1% versus 24.6%, P < 0.01).14 Multivariate analyses
demonstrated infection of tricuspid valves (OR = 3.8, 95% CI 1.2 to 11.9) and surgical
intervention (OR = 5.1, 95% CI 1.6 to 16.3) were significantly associated with recurrent
endocarditis.14
Rodger et al.7 identified 68 PWID with recurrent endocarditis; 22/68 experienced a third
episode and 5/22 experienced a fourth episode. A recurrence rate of 32.1% (68/212) was
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determined among the PWID subjects,7 however, this rate does not consider competing
risks. Conversely, the rate of endocarditis recurrence among non-PWID was much
smaller (32.1% versus 6.2%, P < 0.001). Similar clinical characteristics were observed
for age, sex, HIV status, length of hospital stay, homelessness, site of infection, primary
valve affected, substances used and surgical intervention among first and recurrent
endocarditis episodes.7 Patients who experienced a second episode of endocarditis were
more commonly infected by fungal endocarditis rather than bacterial endocarditis (P =
0.004).7 In addition, Rodger et al.7 found that the odds of mortality were 16.49 (95% CI
1.12 to 243.17, P = 0.041) times greater among PWID patients with fungal infection
compared to those with other types of endocarditis infection, adjusting for surgical
intervention, site of infection and prosthetic valves. Furthermore, among patients with
second episodes of endocarditis, the mortality rate was determined to be 38.2% and the
primary cause of death was observed to be sepsis (81%).7
To date, no studies have been conducted that assess the probability of recurrence of
endocarditis among PWID in the presence of competing risks, a concept that is
imperative to survival analyses. This thesis aimed to bridge this knowledge gap by
conducting a retrospective cohort study utilizing a population-based dataset of
endocarditis and PWID that consists of city-wide data for London, Ontario. This thesis
aimed to identify meaningful risk factors for disease recurrence among PWID and
develop a predictive model with consideration of competing risks. A competing risks
regression analysis was used to provide further context and assess the probability of
disease recurrence in PWID.

2.5 Competing risks
Competing risks data refers to the phenomenon whereby multiple events can occur that
impede the incidence of the outcome of interest.106,107 Competing risks are frequently
disregarded in medical and epidemiological studies, which leads to biased estimates of
the outcome’s cumulative incidence.108 Competing risk models will be further discussed
in Chapter 3: Methods.
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2.6 London, Ontario
Rates of infectious diseases that are frequently associated with IDU, such as HIV and
hepatitis C, have increased among residents of Middlesex-London. The Infectious
Disease Trends in Ontario tool provided by Public Health Ontario109 compares the trends
of HIV (Figure 2.6) and hepatitis C (Figure 2.7) among Middlesex-London and Ontario.
From 2014 to 2017, the rates of HIV in Middlesex-London drastically exceeded that of
Ontario (Figure 2.6). 2016 was observed to have the highest rate of HIV in MiddlesexLondon, reaching a rate of 12.8 per 100,000 population.109 Further, rates of hepatitis C in
Middlesex-London consistently exceeded that of Ontario from 2006 to 2018 (32.7 to 57.5
per 100,000 population [Middlesex-London] versus 31.3 to 36.4 per 100,000 population
[Ontario]) (Figure 2.7).109
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Figure 2.6 Yearly comparison of the rate of HIV in Middlesex-London and Ontario
Source: © Ontario Agency for Health Protection and Promotion (Public Health Ontario). Infectious Disease
Trends in Ontario. Toronto, ON: Queen’s Printer for Ontario; 2020. Available from:
https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/reportable-disease-trendsannually

30

Rate of hepatitis C per 100,000 population
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Figure 2.7 Yearly comparison of the rate of hepatitis C in Middlesex-London and
Ontario
Source: © Ontario Agency for Health Protection and Promotion (Public Health Ontario). Infectious Disease
Trends in Ontario. Toronto, ON: Queen’s Printer for Ontario; 2020. Available from:
https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/reportable-disease-trendsannually

IDU is a predominant issue in London. The I-TRACK survey reported that compared to
the national sample, the probability of injecting opioids was greater among sampled
PWID in London.110 PWID in London were more likely to inject hydromorphone (75.5%
in London versus 47.2% nationally) and morphine (75.5% in London versus 47.0%
nationally).110 Moreover, PWID in London were more likely to lend (26.6% in London
versus 15.5% nationally) and borrow (19.6% in London versus 15.5% nationally) used
injection paraphernalia.110
NEPs in London distribute high volumes of sterile needles to PWID. Each year,
organizations, such as Middlesex-London Health Unit, Regional HIV/AIDS Connection
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and My Sister’s Place, distribute over three million sterile needles in the MiddlesexLondon region to help reduce the incidence of blood-borne diseases.111
In 2012, the seroprevalence of hepatitis C among PWID in London was recorded to be
higher than the national average (79.1% in London versus 68.0% nationally).112 Further, a
report from public health officials of Middlesex-London noted 70% of HIV incident
cases were attributable to IDU in 2016.113 Endocarditis has become an increasingly
significant disease among PWID in Middlesex-London.113 Figure 2.8 illustrates the count
of endocarditis cases among PWID in Middlesex-London from 2008 to 2015. From 2008,
first-episode and recurrent episodes of IDU-related endocarditis have significantly
increased in Middlesex-London.114 Moreover, case-fatality rates of endocarditis among
Middlesex-London PWID range from 30 to 40%.113
80
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Figure 2.8 Number of endocarditis cases among PWID per year in MiddlesexLondon
Source: Dr. Michael Silverman, MD, FRCP, FACP, Chair/Chief Infectious Diseases LHSC and St.
Joseph’s Hospital, Western University, London.
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Chapter 3

3

Methods

This chapter outlines the methods used in this study. Sections 3.1 and 3.2 describe the
data source, its population and setting. Section 3.3 defines the concepts of recurrent
endocarditis and location of infection. Section 3.4 introduces the measures and outcome
variables and provides further information on their coding structure. Section 3.5 provides
information on missing data and how it was handled in this study. Lastly, Section 3.6
outlines the statistical analyses that were conducted to address each of the three research
objectives proposed in this study.

3.1 Data source
This study used a database provided by Dr. Michael Silverman and St. Joseph's Health
Care London, a teaching hospital that encourages the development of education,
healthcare and research.115 The endocarditis database provides demographic and clinical
information on definite endocarditis cases in London, Ontario. Cases were reported using
clinical data from electronic medical records at the London Health Sciences Centre.7 Data
from the electronic medical records includes information on demographics, diagnostic
imaging, microbiology, medication, and clinical notes.7 Data were reviewed by infectious
disease physicians to ensure definite endocarditis criteria was fulfilled as outline by the
Modified Duke Criteria.7 Ethics approval was obtained by Dr. Silverman and colleagues
prior to data collection and retained throughout the current study.

3.2 Population and setting
The database consists of patients admitted to all three acute care hospitals in London,
Ontario, Canada, between April 5, 2007 and March 15, 2018. The study population was
composed of patients 18 years of age or older with definite cases of endocarditis (n =
564). Patients who were not identified as PWID were excluded from the study (n = 254).
The final sample size used in this study was 310 PWID with definite endocarditis. Of the
310 PWID, 236 experienced only a single episode of endocarditis and 74 experienced
two or more episodes. Figure 3.1 illustrates the inclusion/exclusion flowchart for the
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study. Informed consent from participants was not required due to the de-identified and
retrospective nature of the study.
Patients presenting with definite
endocarditis to one of three acute
care hospitals in London, Ontario
(n = 564)
Patients not identified as PWID
excluded from study
(n = 254)

PWID retained in study
(n = 310)

PWID who experienced only a
single episode of endocarditis
(n = 236)

PWID who experienced two or
more episodes of endocarditis
(n = 74)

Figure 3.1 Flowchart of study inclusion and exclusion criteria
Abbreviations: PWID, people who inject drugs.

3.3 Definitions
Definite endocarditis cases were classified as either single or repeat episodes.3 Repeated
cases were defined using criteria proposed in the literature: recurrent episode that either
occurs more than six months from the previous episode OR caused by a different
causative organism.6–8 Microbial culture was used to assess the composition of
vegetations to ensure patients readmitted to hospital for endocarditis less than six months
from the previous episode met the criteria of repeat endocarditis. Each endocarditis
episode may involve multiple admissions and patients may have multiple episodes.
Infections affecting structures on the left side of the heart were defined as left-sided
endocarditis, whereas infections affecting structures on the right side of the heart were
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defined as right-sided endocarditis.7 In cases where structures on both sides of the heart
were affected, endocarditis infection was defined as bilateral.7

3.4 Measures and outcome variables
3.4.1

Demographic variables

Demographic characteristics used in this study include age at time of admission and sex.
Age at time of admission was a continuous variable derived from subtracting the date of
admission from date of birth. Sex was coded as a binary variable whereby 0 represented
female patients and 1 represented male patients.

3.4.2

Exposure variables

Injection drug use. A variable for IDU was created to identify PWID. IDU was recoded
into a binary variable in which 0 represented non-PWID and 1 represented PWID.
Echocardiography. Binary variables for tricuspid, pulmonic, aortic, mitral, right ventricle
or atrium, and device or lead related vegetation were created in which 0 indicated the
absence of valve vegetation and 1 indicated the presence of valve vegetation. Binary
variables for right-sided, left-sided and bilateral endocarditis infection were then created.
Right-sided endocarditis was defined using the presence of vegetation on the tricuspid
valve, pulmonic valve, right ventricle or atrium, and right-sided implantable cardioverterdefibrillator and pacemaker leads. Left-sided endocarditis was defined using the presence
of vegetation on the mitral valve, aortic valve, left-sided interventricular septum and leftsided implantable cardioverter-defibrillator leads. Bilateral endocarditis infection was
defined by the presence of both right-sided and left-sided endocarditis infection.
Subsequently, a categorical variable for the site of infection was then created; 1 indicated
right-sided endocarditis infection only, 2 indicated left-sided endocarditis infection only
and 3 indicated bilateral infection. In situations whereby the sample size is too small to
adequately use the categorical variable, the binary variable for right-sided endocarditis
will be used.
In-hospital treatment. Patient length of stay in days, was a continuous variable derived by
subtracting the date of admission from date of discharge. PICC line misuse, ICU
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admission, surgical intervention, leaving against medical advice and referral to addiction
services were documented as binary variables with the outcomes 0 indicating no and 1
indicating yes.
Drug misuse. A binary variable for polysubstance misuse was created with the outcomes
0 representing mono-substance misuse of either opiates or stimulants, and 1 representing
polysubstance misuse.

3.4.3

Outcome variables

Recurrent endocarditis. The primary outcome of interest for this thesis was the recurrence
of endocarditis. De-identified patient personal identification numbers were used to
identify the number of hospital admissions for definite endocarditis per patient. Hospital
admission for recurrent cases of endocarditis was defined as any hospital readmissions
that either occurred more than six months from the previous episode or whereby
endocarditis infection was caused by a different causative organism. A binary variable for
the presence of recurrent endocarditis was created using these criteria, whereby 0
represented patients who experienced only a single episode of endocarditis and 1
represented patients who experienced two or more episodes of endocarditis. A variable
for the number of recurrent endocarditis episodes per patient was derived using the
number of hospital admissions for definite endocarditis. Due to the small sample size of
patients who went on to experience three episodes (32/74) and four episodes (5/32) of
endocarditis, this variable could not be further broken down for analyses.
Death. Death was treated as a competing risk and recoded as a binary variable in which 0
indicated the patient was alive and 1 indicated patient death. In additional analyses, death
was treated as a primary outcome.

3.4.4

Failure event variables

A categorical variable for survival status was derived to assess the probability of
endocarditis recurrence in the presence of competing risks. Patients who experienced
neither recurrent endocarditis nor death were coded as 0, indicating censoring. Patients
who experienced recurrent endocarditis and either survived or died during the episode
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were coded as 1, indicating observation of the outcome of interest. Patients who died and
did not experience a recurrent episode of endocarditis were coded as 2, indicating the
presence of a competing risk.116 The time-to-event variable was derived by subtracting
the discharge date of the first admission from the date of either readmission, death, or last
follow-up, corresponding to the survival status levels 1, 2 and 0, respectively.
A binary variable for mortality status was derived to measure the probability of mortality
among PWID. Patients who did not experience death were coded as 0, indicating
censoring. Patients who died were coded as 1, indicating observation of the outcome of
interest. The time-to-death variable was derived by subtracting the discharge date of the
first admission from the date of either death or last follow-up, corresponding to the
survival status levels 1 and 0, respectively.

3.5 Missing data
Missing data is a common occurrence in epidemiological studies and requires careful
consideration when conducting statistical analyses as inaccurate and biased results may
be produced.117 There are three primary categories of missing data, (i) missing
completely at random (MCAR), (ii) missing at random (MAR) and (iii) missing not at
random (MNAR).117 Missing data is designated as MCAR when the missingness is not
dependant on the observed or unobserved variables.117 Data is denoted MAR when the
probability of missingness is not dependent on unobserved data.117 Conversely, when the
probability of missingness is dependent on unobserved data, the data is said to be
MNAR.117
Of the three types of missingness, MCAR is the only one that can be assessed. MCAR
can be evaluated by (1) assessing the distribution of the data using summary statistics and
(2) assessing the relationship between the missingness and covariates using logistic
regression. If the missing data are MCAR in nature, there will be no differences between
observations with complete data and those with missing data.118 Therefore, binary
missing data indicators will be generated for each variable with missing data and assessed
using summary statistics and logistic regression. If the results determine that the
missingness of the data is not MCAR, multiple imputation will be used. If the missing
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data is determined to be MCAR, complete case analysis of observations with complete
data will be used.119
Multiple imputation is a common method used for handling missing data and consists of
three stages: imputation, complete-data analysis and pooling.120 The imputation phase
replaces missing values with a random sample of probable imputation values generated
using observations with complete data; multiple datasets are created using this
technique.121 Next, statistical analyses are conducted for each dataset.121 Finally, the
results obtained for each dataset are combined to generate a multiple imputation result.121
There are two primary approaches to multiple imputation, the multivariate normal
imputation and the fully conditional specification (FCS).122 In the multivariate normal
imputation approach, imputed values are obtained using a Bayesian technique, which
allows for the ascertainment of uncertainty levels in model parameter coefficients.122
Furthermore, this model assumes each variable follows a multivariate normal
distribution.122 Conversely, the FCS approach is not dependent on the assumption of
normality, making this approach much more flexible.122 The FCS approach generates
regression models for each variable containing missing data that are conditional on the
variables in the desired imputation model.122 Estimates of each conditional regression
model using cases with complete data generates imputations and allows for ascertainment
of uncertainty levels in model parameter coefficients.122
In the presence of binary and categorical variables, the assumption of multivariate
normality is not always reasonable, thus, use of multivariate normal imputation is not
plausible.122 Further, the FCS approach generates regression models for each variable,
allowing for flexibility in imputation.122 Since the dataset used in this study contains
continuous, binary and categorical variables, the FCS approach to imputation was used to
handle missing data.122

3.6 Statistical analyses
Analyses of missing data were conducted using SAS 9.4®.123 Survival plots were created
using SAS 9.4®123 and R®.124 All other analyses were conducted using Stata/IC 16.1.125

38

The following sections discuss the statistical methods used to address the objectives and
research questions proposed in the study.

3.6.1

Characterizing important factors that contribute to the
recurrence of endocarditis among PWID in London, Ontario

To address objective 1 and the research question, “what are the key factors that contribute
to the recurrence of endocarditis among PWID in London, Ontario?”, descriptive
analyses were conducted comparing patient characteristics between PWID who only
experienced a single episode of endocarditis and PWID who went on to experience
recurrent (≥ two) endocarditis episodes. Pearson's chi-squared and Wilcoxon rank sum
tests were conducted for binary/categorical and continuous variables, respectively, to
determine if the distribution of variables is equivalent across the two strata. Next,
bivariate analyses of the primary outcome and exposure variables of interest were
conducted to assess empirical relationships between recurrent endocarditis and
independent demographic and exposure variables. Further, to assess the extent to which
important factors contribute to the recurrence of endocarditis among PWID in London,
Ontario, a complete case multivariate logistic regression analysis and FCS imputation
logistic regression analysis were subsequently conducted. Multicollinearity was assessed
between predictors of interest to ensure the variables were not linearly related. Model
covariates were chosen based on subject matter knowledge. The model included age,9,10
sex,9 substance use,66,101,126 location of infection,126 and surgical intervention78,126 as
covariates, as proposed by current literature. Further, this study aimed to assess the
effects of length of hospital stay, PICC line misuse, addiction referral, leaving against
medical advice and admission to the ICU. The model can be written as follows,
𝑃(𝒙)
= exp(𝛽0 + 𝛽1 𝑎𝑔𝑒 + 𝛽2 𝑠𝑒𝑥 + 𝛽3 𝐿𝑂𝑆 + 𝛽4 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛 + 𝛽5 𝑠𝑢𝑟𝑔𝑒𝑟𝑦 + 𝛽6 𝑃𝐼𝐶𝐶 + 𝛽7 𝑎𝑑𝑑𝑖𝑐𝑡𝑖𝑜𝑛
1 − 𝑃(𝒙)
+ 𝛽8 𝐴𝑀𝐴 + 𝛽9 𝑠𝑢𝑏𝑠𝑡𝑎𝑛𝑐𝑒 + 𝛽10 𝐼𝐶𝑈)

where P represents the probability that the event of interest will occur, x represents
predictor variables, LOS represents length of hospital stay, PICC represents PICC line
misuse and AMA represents leaving against medical advice. Coefficients were assessed
for the direction and magnitude of effect of each independent predictor on the recurrence
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of endocarditis. Significance was indicated using Wald test statistics, two-sided
confidence intervals and P values < 0.05.

3.6.2

Survival analysis

To assess the probability of endocarditis recurrence in the presence of competing risks
among PWID in London, Ontario, survival analyses were conducted. Survival analysis is
a division of statistics that consists of a set of methods for which the outcome of interest
is the time until an event occurs, known as time-to-event data.127,128 Time-to-event
endpoints often include death, time to relapse, time to disease progression or any
outcome of interest that occurs within the patient population.128,129 An outcome of interest
can be defined as either a success or failure.128,130 Events denoted failures, such as death
or disease incidence, are often of greater clinical significance.128,130
Survival analyses are comprised of two functions, the survivor function and the hazard
function. The survivor function, denoted 𝑆(𝑡), describes the time in which a patient has
survived over a follow-up period,128,129 and is given by
𝑆(𝑡) = Pr(𝑇 > 𝑡)
where T represents a patient’s survival time and t represents a specific value of interest
for T.128 The overall probability of survival among patients is estimated using event status
and person follow-up time.131 A patient’s probability of survival is conditional on the
patient surviving for a specified amount of time in which they are at risk of experiencing
the outcome.131 Conversely, the hazard function represents the short-term event rate for
patients who are still at risk (survived up to time t) of experiencing the outcome of
interest107 and is given by
𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑇 ≥ 𝑡)
∆𝑡→0
∆𝑡

ℎ(𝑡) = lim

The hazard ratio (HR) is the measure of effect obtained from survival analyses.128 The
hazard ratio is defined as the ratio of hazards between exposed and unexposed patients132
and is given by
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𝐻𝑅(𝑡) =

ℎ1 (𝑡)
ℎ0 (𝑡)

where ℎ1 (𝑡) is the hazard of the exposed patients and ℎ0 (𝑡) is the hazard of the
unexposed patients.
The Cox proportional-hazards regression model is used to assess the association between
multiple predictors and a time-to-event outcome.107 We assume a proportional hazards
model as,107
ℎ(𝑡|𝒙) = ℎ0 (𝑡)exp(𝛽1 𝑎𝑔𝑒 + 𝛽2 𝑠𝑒𝑥 + 𝛽3 𝐿𝑂𝑆 + 𝛽4 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛 + 𝛽5 𝑠𝑢𝑟𝑔𝑒𝑟𝑦 + 𝛽6 𝑃𝐼𝐶𝐶𝑚𝑖𝑠𝑢𝑠𝑒
+ 𝛽7 𝑎𝑑𝑑𝑖𝑐𝑡𝑖𝑜𝑛 + 𝛽8 𝐴𝑀𝐴 + 𝛽9 𝑠𝑢𝑏𝑠𝑡𝑎𝑛𝑐𝑒 + 𝛽10 𝐼𝐶𝑈)

where x represents predictor variables, ℎ0 (𝑡) represents the baseline hazard function,
LOS represents length of hospital stay, PICC represents PICC line misuse and AMA
represents leaving against medical advice.
A unique feature of survival analysis is its ability to allow for incompletely determined
responses for some patients,127 which are often considered ‘censored data’. Censored data
refers to the phenomenon whereby some information is known about the patient’s
survival time, however, the exact survival time is unknown.128 Essentially, a patient’s
data is censored when the outcome of interest has not been observed.133 Censoring of
time-to-event data usually occurs when (i) the patient is lost to follow-up, (ii) the patient
does not experience the event prior to the end of the study, or (iii) the patient dies or is
withdrawn from the study.128 Right-censoring occurs when the true survival time at time t
is greater than or equal to the survival time observed at time t.107,128,133

3.6.2.1

Competing risks

Competing risks data refers to the phenomenon whereby multiple events can occur that
impede the occurrence of the outcome of interest.106,107 In terms of recurrence of
endocarditis, death is considered a competing risk as it impedes a patient’s ability to be
reinfected by the disease. The presence of competing risks hinders the use of traditional
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survival analysis methods, such as Kaplan–Meier methods, as “event time is neither
observed nor censored”.129
Competing risks are common in practice and are often ignored. A survey by van
Walraven and McAlister,134 observed 46% (46/100) of studies were biased by competing
risks, of which, 37.5% produced estimates that were overestimated by ≥ 10%. These
studies typically used traditional Kaplan–Meier methods, which censor competing
risks.129,134
In the presence of competing risks, the cumulative incidence function (CIF) and causespecific hazard function (CSH)—analogs of the survivor and hazard functions,
respectively—are used. The CIF describes the probability of experiencing an event (j) by
time t107,129 and is given by
𝐶𝐼𝐹𝑘 (𝑡) = 𝑃(𝑇 ≤ 𝑡, 𝛿 = 𝑗),𝑗 = 1, … , 𝐽.
Conversely, the CSH describes the short-term rate of occurrence of the jth event (denoted
failure) in patients who are event free,106,107,129 and is given by,135
Pr(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡, 𝐷 = 𝑗|𝑇 ≥ 𝑡)
.
∆𝑡→0
∆𝑡

ℎ(𝑡) = 𝜆𝑗𝑐𝑠 (𝑡) = lim

where 𝜆𝑗𝑐𝑠 represents the CSH for the jth event among subjects that are event-free and D
represents the type of event that occurred.106,136 The CSH describes the instantaneous rate
of failure from each event type in patients who are event free up to time t.129 As a result,
the risk set for the CSH includes patients who are currently event free.129
An analog of the relationship between the survivor function and hazard function is
defined by the subdistribution hazard (SH), proposed by Fine and Gray.137 The SH
describes the instantaneous rate of an event given no other event, competing or otherwise,
has occurred before time t.129 We assume a proportional hazards model for the SH
function as,135
Pr(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡, 𝐷 = 𝑗|𝑇 ≥ 𝑡 ∪ (𝑇 < 𝑡 ∩ 𝐷 ≠ 𝑗))
∆𝑡→0
∆𝑡

ℎ(𝑡) = 𝜆𝑗𝑠𝑑 (𝑡) = lim
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where 𝜆𝑗𝑠𝑑 represents the SH for the jth event among subjects who have not experienced
the event of type j and D represents the type of event that occurred.106,136 In contrast to
CSH, the risk set of SH includes patients who are currently event free and patients who
have experienced a competing risk.129
Competing risk survival data can be modeled using either the cause-specific Cox
regression model or the Fine–Gray model. Both models are adequate for assessing
competing risk survival data, however, they differ in terms of their relationship with the
CIF, interpretation, application of proportional-hazards model and proportional hazards
assumptions.129 The choice of which model to use is often driven by the type of research
question investigators wish to answer. Etiologic-based research questions, which aim to
identify the effects of exposures on a disease, are answered using the cause-specific Cox
regression model, whereas prognostic-based research questions, which aim to address
disease progression or likelihood, are answered using the Fine–Gray model.129,138 This
thesis aims to address the probability of endocarditis recurrence in the presence of death
as a competing risk, therefore, the Fine–Gray model will be used.

3.6.3

Measuring the probability of endocarditis recurrence in the
presence of competing risks among PWID in London,
Ontario

To address Objective 2 and the research question, “what is the probability of the
recurrence of endocarditis among PWID in London, Ontario, in the presence of
competing risks?”, the CIF of endocarditis recurrence was assessed and graphed. Time at
risk was defined as the time from hospital discharge from the first admission until either
readmission for a second episode of endocarditis or death. While traditional Kaplan–
Meier methods overestimate the probability of an event occurring in the presence of
competing risks, this study conducted both Kaplan–Meier and Fine–Gray estimates to
demonstrate the importance of accounting for competing risks.
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3.6.4

Assessing the associations of survival time and predictor
variables among PWID in London, Ontario

This study used the Fine–Gray model to develop a predictive model to address Objective
3 and the research question, “what is the association between survival time and predictor
variables accounting for death as a competing risk?”. Competing risk survival analyses
were conducted to investigate the association of recurrent endocarditis and predictors of
interest. The model for recurrence among PWID included age, sex, length of stay, PICC
line misuse, location of infection, surgical intervention, leaving against medical advice,
admission to the ICU, referral to addiction services and type of substance misused. Time
at risk was defined as the time from hospital discharge from the first admission until
either readmission for a second episode of endocarditis or death. Significance was
determined using Wald test statistics, two-sided confidence intervals and P values < 0.05.

3.6.5

Evaluating the associations of mortality and predictor
variables among PWID in London, Ontario

Since death is a definitive time-to-event endpoint, competing risks do not need to be
considered. Therefore, it is feasible to conduct traditional Kaplan–Meier and Cox
proportional hazards regression analyses to investigate the relationship between mortality
and predictors of interest. The model for mortality included age, sex, length of stay, PICC
line misuse, location of infection, surgical intervention, leaving against medical advice,
admission to the ICU, referral to addiction services, type of substance misused and
recurrent endocarditis. Time at risk was defined as the time from hospital discharge from
the first admission until death. Significance was determined using Wald test statistics,
two-sided confidence intervals and P values < 0.05.

3.6.5.1

Immortal time bias

Immortal time bias is defined as a period of follow-up time of a cohort in which it is not
plausible for the outcome of interest to have occurred.139 This type of bias is primarily
observed in studies that evaluate the effect of a treatment on survival.140 A key aspect of
immortal time bias is that the exposure classification requires individuals to survive until
the date they receive treatment.140 Individuals who die prior to receiving treatment are
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deemed unexposed, creating a false sense of survival advantage for exposed
individuals.140 Analyses that fail to account for such bias underestimate the hazard ratio
and provide false conclusions regarding treatment effectiveness.141 There are two main
approaches that account for immortal time bias, (1) matching and (2) using timedependent covariates.142 Matching occurs in the study design stage and consists of pairing
individuals who share similar baseline characteristics but differ with respect to treatment
status.142,143 In observational studies, pairs are matched based on covariate values or
propensity score.143 In contrast, a time-dependent covariate is a predictor in a Cox model
whose value may differ over time.107,142 Due to the retrospective nature of the current
study, surgical intervention and recurrent endocarditis were treated as time-dependent
covariates to account for immortal time bias.
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Chapter 4

4

Results

This chapter presents the study’s findings. Section 4.1 highlights the results of the
descriptive analyses of the baseline characteristics of single and recurrent endocarditis
episodes among PWID. Missing data diagnostics are covered in Section 4.2. Section 4.3
presents the results of the bivariate and multivariate logistic regression analyses and
addresses Objective 1 of the study, characterizing important factors that contribute to the
recurrence of endocarditis among PWID in London, Ontario. Section 4.4 evaluates
multicollinearity between predictor variables. The CIF of endocarditis recurrence with
consideration for death as a competing risk is estimated and modeled in Section 4.5 and
addresses Objective 2 of the study, estimating the probability of disease recurrence in the
presence of competing risks among PWID in London, Ontario. Objective 3, assessing the
associations of survival time and predictor variables among PWID in London, Ontario, is
addressed in Sections 4.6 to 4.8. Section 4.6 assesses the associations between
endocarditis recurrence and predictors of interest in the presence of competing risks.
Section 4.7 models the Kaplan–Meier failure function for mortality among the PWID
population. Finally, Section 4.8 presents the results of the bivariate and multivariate timedependent Cox proportional-hazards regression analyses.

4.1 Descriptive analyses
Among the study population, 236 PWID experienced a single episode of endocarditis,
whereas 74 experienced recurrent episodes of endocarditis. Consequently, the rate of
recurrence among the study population was determined to be 23.9% (74/310).
To determine whether the mean and standard deviation or the median and IQR should be
used to assess the continuous variables in the dataset, boxplots for the variables age and
length of hospital stay were created to identify their distributions (Figure 4.1). The
boxplots for age and length of hospital stay demonstrate right-skewedness, indicating the
presence of outliers. As a result, the median and IQR were used to assess age and length
of hospital stay.
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Figure 4.1 Boxplots demonstrating the distribution of age and length of stay
stratified by single and recurrent endocarditis episodes
Table 4.1 illustrates the baseline characteristics of patients stratified by endocarditis
status (those who only experienced a single episode of endocarditis and those who went
on to experience recurrent endocarditis episodes). The median age at time of admission
was identical between patients who experienced a single episode of endocarditis and
those who experienced recurrent episodes. Similarly, sex of the patients was evenly
distributed across both strata. The median length of hospital stay was slightly higher
among patients who would go on to experience recurrent episodes compared to patients
who only experienced one episode (P = 0.04). Echocardiographic characteristics were
similar among both single and recurrent episodes. The tricuspid valve was the primary
cardiac structure affected among both single and recurrent episodes. However, infection
of the tricuspid valve occurred more frequently among PWID who went on to experience
recurrent episodes of endocarditis (66.2% versus 82.2%, P = 0.01). The distribution of
location of infection differed significantly across strata (P = 0.04). Right-sided infection
was the predominant type of endocarditis among both single and recurrent episodes but
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observed to be more frequent among PWID who went on to experience recurrent
episodes of endocarditis (61.4% versus 75.3%). Furthermore, the distribution of left-sided
infection was found to be significantly different between patients who only experienced a
single episode compared to those who would go on to experience recurrent episodes.
Left-sided endocarditis infection was observed less frequently among PWID who went
on to experience recurrent episodes of endocarditis (31.6% versus 16.4%). The
distribution of PICC line misuse differed significantly between the two strata (P < 0.001).
Among single episodes, PICC line misuse was relatively low (19.0%). Conversely, the
proportion of patients who misused their PICC line increased among those who would go
on to experience recurrent episodes (43.8%). Referral to addiction services was also
higher among those who went on to experience a recurrent episode compared to those
who experienced a single episode (45.9% versus 31.5%, P = 0.02). Polysubstance misuse
of opiates and stimulants was found in higher proportions among single and recurrent
episodes (64.7% and 65.3%, respectively) compared to substance misuse of either opiates
or stimulants alone, however the difference in distribution across strata was not found to
be statistically significant (P = 0.93). The proportion of patients who underwent cardiac
surgery was low in both strata (single episode: 17.3% versus recurrent episodes: 17.6%).
This slight difference in distribution was not statistically significant (P = 0.97). Patients
who went on to experience recurrent episodes of endocarditis had a slightly lower
proportion of ICU admissions than single episode cases (29.7% versus 36.0%), which
was found to not be statistically significant (P = 0.32). A slightly higher proportion of
patients who experienced recurrent episodes left against medical advice compared to
patients who experienced a single episode (25.7% versus 20.3%, respectively), however,
this difference was not statistically significant (P = 0.33).
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Table 4.1 Baseline characteristics from initial hospitalization stratified by patients
who only experienced a single episode of endocarditis and those who went on to
experience recurrent endocarditis episodes among PWID
Number of Episodes Experienced
Single Episode
(n = 236)

≥ Two Episodes
(n = 74)

P-value

Age (years), median [IQR]
34.0 [28.0–43.0]
34.0 [28.0–41.0]
0.53
Sex, n (%)
0.60
Female
113 (47.9)
38 (51.3)
Male
123 (52.1)
67 (48.7)
Primary valve infected, n (%)
Tricuspid
151 (66.2)
60 (82.2)
0.01
Pulmonic
3 (1.32)
1 (1.4)
0.97
Mitral
53 (23.3)
10 (13.7)
0.08
Aortic
47 (20.6)
8 (11.0)
0.06
Right ventricle/atrium
6 (2.6)
2 (2.7)
0.96
Unknown
8
1
Site of infection, n (%)
0.04
Right-sided
140 (61.4)
55 (75.3)
Left-sided
72 (31.6)
12 (16.4)
Bilateral
16 (7.0)
6 (8.2)
Unknown
8
1
Length of hospital stay, median
25.6 [12.8–45.0]
33.0 [16.0–57.0]
0.04
[IQR]
PICC misuse, n (%)
< 0.001
No
187 (81.0)
41 (56.2)
Yes
44 (19.0)
32 (43.8)
Unknown
5
1
Surgical intervention, n (%)
0.97
No
195 (82.6)
61 (82.4)
Yes
41 (17.4)
13 (17.6)
Admission to the ICU, n (%)
0.32
No
151 (64.0)
52 (70.3)
Yes
85 (36.0)
22 (29.7)
Substance misuse, n (%)
0.93
Opiate or stimulant only
73 (35.3)
25 (34.7)
Polysubstance
134 (64.7)
47 (65.3)
Unknown
29
2
Referral to addiction services, n (%)
0.02
No
161 (68.5)
40 (54.1)
Yes
74 (31.5)
34 (45.9)
Unknown
1
Left AMA, n (%)
0.33
No
188 (79.7)
55 (74.3)
Yes
48 (20.3)
19 (25.7)
Abbreviations: IQR, interquartile range; PICC, peripherally inserted central catheter; ICU, intensive care
unit; AMA, against medical advice.
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4.2 Analysis of missing data
Missing data was assessed for the variables used in subsequent multivariate analyses
(Table 4.2). Approximately 84.8% (263/310) of the observations were complete for all
variables. Of the missing data, 14.2% (44/310) of observations were missing data for one
variable and 0.96% (3/310) of observations were missing data for two variables.
Table 4.2 Missingness of variables used in analyses
Variable

N

N Missing

% Missing

Observations
310
47
15.2%
Demographic variables
Age at admission
310
0
0.0%
Sex
310
0
0.0%
Length of hospital stay
310
0
0.0%
Exposure variables
Endocarditis Location
301
9
2.9%
PICC misuse
304
6
1.9%
Addiction services referral
309
1
0.3%
Left AMA
310
0
0.0%
Admission to the ICU
310
0
0.0%
Surgical intervention
310
0
0.0%
Confirmed in-hospital drug use
310
0
0.0%
Substance misuse
279
31
10.0%
Outcome variables
Recurrent endocarditis
310
0
0.0%
Survival status
310
0
0.0%
Time-to-event
307
3
1.0%
Abbreviations: PICC, peripherally inserted central catheter; AMA, against medical advice; ICU, intensive
care unit.

Formal assessment of MCAR was conducted using summary statistics and Little’s test for
MCAR.144,145 Due to the small proportion of missing data per variable in Table 4.2, it was
not feasible to evaluate the relationship between the missingness and covariates using
logistic regression. Table 4.3 illustrates the summary statistics for each missing data
indicator and covariates.
The distribution of PICC line misuse was seen to vary across missing and observed
values for location of endocarditis infection. Among patients missing information
regarding the location of infection, approximately 11.1% misused their PICC line.
Conversely, 25.4% of patients with information regarding the location of infection
misused their PICC line. Similar divergences are seen for male sex (observed: 50.5%
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versus missing: 77.8%), median length of hospital stay (observed: 29.0 days versus
missing: 11.0 days), admission to the ICU (observed: 34.2% versus missing: 44.4%),
surgical intervention (observed: 17.9% versus missing: 0.0%), disease recurrence
(observed: 24.3% versus missing: 11.1%), percent of patients censored (observed: 52.8%
versus missing: 66.7%) and median time-to-event (observed: 17.0 months versus missing:
44.0 months). In contrast, the distributions of addiction referral, substance type, age, and
leaving against medical advice were similar across missing and observed values. These
results suggest that the distribution of PICC line misuse, sex, length of hospital stay,
admission to the ICU, surgical intervention, disease recurrence, survival status, and timeto-event varies across missing and observed values for location of infection and provide
evidence against MCAR.
Similar distributions for median age, median length of hospital stay, and median time-toevent were observed for missing and observed values of PICC line misuse. The
distributions of location of infection (observed: 65.1% versus missing: 50.0%), addiction
referral (observed: 34.3% versus missing: 66.7%), substance type (observed: 64.2%
versus missing: 100.0%), male sex (observed: 51.0% versus missing: 66.7%), admission
to the ICU (observed: 34.9% versus missing: 16.7%), surgical intervention (observed:
17.1% versus missing: 33.3%), leaving against medical advice (observed: 21.4% versus
missing: 33.3%), disease recurrence (observed: 24.0% versus missing: 16.7%) and
percent of patients censored (observed: 52.6% versus missing: 83.3%) varied across
missing and observed values of PICC line misuse.
The distributions of location of infection (observed: 68.6% versus missing: 30.0%), PICC
line misuse (observed: 27.7% versus missing: 0.0%), addiction referral (observed: 38.1%
versus missing: 6.5%), male sex (observed: 48.8% versus missing: 74.2%), median length
of hospital stay (observed: 31.0 days versus missing: 15.0 days), admission to the ICU
(observed: 31.2% versus missing: 64.5%), surgical intervention (observed: 15.4% versus
missing: 35.5%), leaving against medical advice (observed: 23.3% versus missing: 6.5%)
and disease recurrence (observed: 25.8% versus missing: 6.5%) varied across missing
and observed values of substance type. In contrast, median age, survival status and
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median time-to-event had similar distributions for missing and observed values of
substance type.
The distributions of addiction referral, median age, and admission to the ICU were
similar across missing and observed values for time-to-event. In contrast, the
distributions of location of infection (observed: 65.1% versus missing: 33.3%), PICC line
misuse (observed: 24.5% versus missing: 100.0%), substance type (observed: 64.5%
versus missing: 100.0%), male sex (observed: 51.1% versus missing: 66.7%), median
length of hospital stay (observed: 29.0 days versus missing: 39.0 days), surgical
intervention (observed: 17.3% versus missing: 33.3%), leaving against medical advice
(observed: 21.2% versus missing: 66.7%), disease recurrence (observed: 24.1% versus
missing: 0.0%) and percent of patients censored (observed: 52.7% versus missing:
100.0%) varied across missing and observed values of time-to-event.
Since there was only a single missing value for addiction referral, it was not reasonable to
determine if the MCAR assumption was violated.
To further assess whether the missing data is MCAR, Little’s test of MCAR was
conducted. The results of Little’s test gave a P-value < 0.001. This provides evidence that
the variables, location of infection, PICC line misuse, referral to addiction services,
substance type misused and TTE are not MCAR under a 0.05 significance level.145
From the results, it can be determined that the missing indicators for location of infection,
PICC line misuse, substance type and time-to-event do not comply with the MCAR
assumption that there are no differences between observations with complete data and
those with missing data. Therefore, FCS imputation analysis will be conducted jointly
with the multivariate logistic regression and survival analyses.
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Table 4.3 Summary statistics of levels of missing indicators for variables location, PICC line misuse, addiction referral,

Location
(% RSIE)

% PICC
misused

% Addiction
referral

%
Polysubstance

Age (median)

% Male

LOS (median)

% ICU

% Surgery

% Left AMA

% Recurrent
episode

% Censored

TTE (median)

substance type and time-to-event

Observed

-

25.4%

35.0%

64.9%

34.0

50.5%

29.0

34.2%

17.9%

21.6%

24.3%

52.8%

17.0

Missing

-

11.1%*

33.3%

62.5%

35.0

77.8%*

11.0*

44.4%*

0.0%*

22.2%

11.1%*

66.7%*

44.0*

Observed

65.1%

-

34.3%

64.2%

34.0

51.0%

29.0

34.9%

17.1%

21.4%

24.0%

52.6%

18.0

Missing

50.0%*

-

66.7%*

100.0%*

34.5

66.7%*

24.5

16.7%*

33.3%*

33.3%*

16.7%*

83.3%*

14.0

64.7%

25.1%

-

64.8%

34.0

51.1%

29.0

34.6%

17.5%

21.7%

24.0%

53.1%

17.5

100.0%*

0.0%*

-

100.0%*

50.0

100.0%*

15.3

0.0%*

0.0%

0.0%*

0.0%*

100.0%

129.0*

68.6%

27.7%

38.1%

-

34.0

48.8%

31.0

31.2%

15.4%

23.3%

25.8%

53.8%

17.5

Missing

30.0%*

0.0%*

6.5%*

-

32.0

74.2%*

15.0*

64.5%*

35.5%*

6.5%*

6.5%*

48.4%

19.0

Observed

65.1%

24.5%

35.0%

64.5%

34.0

51.1%

29.0

34.5%

17.3%

21.2%

24.1%

52.7%

-

Missing

33.3%*

100.0%

33.3%

100.0%

37.0

66.7%*

39.0*

33.3%

33.3%*

66.7%*

0.0%*

100.0%

-

Missingness Indicator

Location

PICC misuse

Addiction referral†

Observed
Missing
Observed

Substance type

TTE

Abbreviations: RSIE, right-sided endocarditis infection; PICC, peripherally inserted central catheter; ICU, admission to the ICU; AMA, against medical advice;
TTE, time-to-event.
* indicates varying distributions for values of missing indicators.
† there is only one missing value for addiction referral, therefore, MCAR cannot be determined.
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4.3 Logistic regression analyses
4.3.1

Bivariate logistic regression analyses

Bivariate analyses of the empirical association between the predictors of interest and
recurrent endocarditis among PWID is shown in Table 4.4. Study results demonstrate that
for each day increase in the length of hospital stay, a patient’s odds of developing
recurrent endocarditis significantly increased by 1% (OR = 1.01, 95% CI 1.00 to 1.02, P
= 0.002). Similarly, for patients that misused their PICC line, the odds of developing
recurrent endocarditis were found to be 3.32 (95% CI 1.88 to 5.85, P < 0.001) times
higher compared to patients who did not misuse their PICC line. Moreover, the odds of
developing recurrent endocarditis were found to significantly increase almost 2-fold (OR
= 1.85 95% CI 1.09 to 3.15, P = 0.02) for patients who were referred to addiction
services compared to those who were not referred to addiction services. Left-sided
infection was the only variable found to significantly decrease the odds of developing
recurrent endocarditis (P = 0.01). The odds of developing recurrent endocarditis were
found to significantly decrease in patients with left-sided infection (OR = 0.42, 95% CI
0.21 to 0.84) compared to patients with right-sided infection. Age, sex, bilateral infection,
surgical intervention, admission to the ICU, polysubstance misuse and leaving against
medical advice were not found to be statistically associated with the odds of developing a
recurrent episode of endocarditis among the study population.

4.3.2

Multivariate logistic regression analyses

Results of the CCA and FCS imputation of the multivariate logistic analysis of the
association between the predictors of interest and recurrent endocarditis among PWID is
shown in Table 4.4. Similar results were obtained for both CCA and FCS analyses.
Multivariate analysis demonstrated PICC line misuse to be statistically associated with
the odds of developing recurrent endocarditis (CCA: P = 0.005, FCS: P = 0.006). PICC
line misuse was found to be associated with a 2.54 to 2.62 increase in adjusted odds of
developing recurrent endocarditis (CCA: OR = 2.62, 95% CI 1.34 to 5.14; FCS: OR =
2.54, 95% CI 1.30 to 4.94) compared to patients who did not misuse their PICC line.
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Table 4.4 Bivariate and multivariate logistic regression for recurrent infective endocarditis in PWID

Age
Sex (ref=female)
Length of hospital stay
Location of infection (ref = right-sided IE)
Left-sided
Bilateral
PICC line misuse (ref = no misuse)
Referral to addiction services (ref = not referred)
Surgical intervention (ref = no surgery)
Admission to the ICU (ref = not admitted)
Misuse of Opiates and Stimulants (ref = opiate or
stimulant use only)
Left AMA (ref = did not leave AMA)

OR
0.99
0.87
1.01

Bivariate Analysis
95% CI
P-value
0.96
1.01
0.34
0.52
1.47
0.60
1.00
1.02
0.002

CCA Multivariate Analysis
ORa
95% CI
P-value
1.00
0.97
1.03
0.93
1.66
0.88
3.12
0.12
1.00
1.00
1.01
0.28

FCS Multivariate Analysis
ORa
95% CI
P-value
1.00
0.97
1.03
0.89
1.21
0.62
2.23
0.53
1.01
1.00
1.01
0.22

0.42
0.96
3.32
1.85
1.01
0.75

0.21
0.34
1.88
1.09
0.51
0.43

0.84
2.57
5.85
3.15
2.02
1.32

0.01
0.93
< 0.001
0.02
0.97
0.32

0.52
0.84
2.62
1.36
1.55
0.91

0.23
0.27
1.34
0.74
0.65
0.46

1.21
2.66
5.14
2.49
3.72
1.80

0.13
0.77
0.005
0.32
0.33
0.79

0.51
0.93
2.54
1.35
1.52
0.89

0.23
0.32
1.30
0.75
0.67
0.47

1.12
2.67
4.94
2.40
3.44
1.69

0.09
0.89
0.006
0.32
0.31
0.72

1.02

0.58

1.80

0.93

0.96

0.51

1.81

0.90

0.94

0.51

1.74

0.83

1.35

0.74

2.49

0.33

0.81

0.39

1.68

0.57

0.94

0.47

1.88

0.86

Values in bold indicate statistical significance (P < 0.05).
Abbreviations: CCA, complete case analysis; FCS, fully conditional specification; OR, odds ratio; CI, confidence interval; PICC, peripherally inserted central
catheter; ICU, intensive care unit; AMA, against medical advice.
a

Adjusted ORs were generated from multivariable logistic regression models. The CCA and FCS models were adjusted for age, sex, length of hospital stay,

location of infection, PICC line misuse, referral to addiction services, surgical intervention, ICU admission, substance misused and leaving AMA.
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4.4 Multicollinearity
Multicollinearity was assessed among variables to ensure redundancy of information was
excluded. Diagnostic results of multicollinearity are displayed in Table 4.5. The variance
inflation factor (VIF) determines the amount of multicollinearity among variables,
whereas tolerance (1/VIF) refers to the degree of multicollinearity among variables.146 As
a general rule, VIFs over 10 and tolerances lower than 0.1 imply the need for further
investigation.146 Table 4.5 demonstrates adequate VIF and tolerance values, indicating
the lack of multicollinearity among the chosen predictors.
Table 4.5 Multicollinearity diagnostics
Age
Sex
Length of hospital stay
Location of infection
Surgery
PICC misuse
Substance misuse
Addiction services
referral
Left AMA
Admission to the ICU
Mean VIF

VIF
1.26
1.16
1.20
1.17
1.21
1.30
1.14
1.12

√VIF
1.12
1.08
1.10
1.08
1.10
1.14
1.07
1.06

Tolerance
0.80
0.86
0.83
0.85
0.83
0.77
0.88
0.90

R2
0.20
0.14
0.17
0.15
0.17
0.23
0.12
0.10

1.19
1.17

1.09
1.08

0.84
0.86

0.16
0.14

1.19

Abbreviations: VIF, variance inflation factor; R2, coefficient of determination; PICC, peripherally inserted
central catheter; AMA, against medical advice; ICU, intensive care unit.

4.5 Cumulative incidence function for endocarditis
recurrence in the presence of death
The Fine–Gray model for competing risks was used to estimate the CIF for recurrent
endocarditis and death. Of the 310 patients, 53.2% (165/310) were censored, 23.9%
(74/310) experienced a recurrent episode of endocarditis and 22.9% (71/310) died
without experiencing a recurrent episode of endocarditis. Figure 4.2 illustrates the CIF
estimate for recurrent endocarditis episodes in the presence of death as a competing risk
for PWID. At 93 months, the CIF of endocarditis recurrence among PWID was estimated
to be 0.38 (95% CI 0.29 to 0.47).
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Figure 4.2 Estimate of the cumulative incidence function for recurrent endocarditis
with consideration for death as a competing risk

4.5.1

Comparing the Fine–Gray and Kaplan–Meier methods

As previously mentioned in Chapter 3: Methods, the Kaplan–Meier failure function fails
to account for competing risks and produces results that overestimate the incidence of the
event of interest. When accounting for the competing risk of death, the cumulative
incidence of endocarditis recurrence among PWID was estimated to be 0.38 (95% CI
0.29 to 0.47) at 93 months. However, when using the Kaplan–Meier failure function,
which censors competing risks, the failure probability at 93 months was estimated to be
0.41 (95% CI 0.31 to 0.52) (Figure 4.3). Consequently, censoring death rather than taking
it into account resulted in an absolute difference of 3.0%.
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Figure 4.3 Kaplan–Meier failure estimator for recurrent endocarditis

4.6 Fine–Gray subdistribution hazard regression analyses
4.6.1

Bivariate Fine–Gray subdistribution hazard regression
analysis for recurrent endocarditis

Bivariate Fine–Gray subdistribution hazard regression analyses were used to describe the
association between recurrent endocarditis and predictors of interest. Results of the
regression analysis are displayed in Table 4.6. Length of hospital stay was found to be
significantly associated with the subdistribution hazard ratio (SHR) of endocarditis
recurrence (SHR = 1.01, 95% CI 1.00 to 1.01, P < 0.001) at the bivariate level.
Additionally, PICC line misuse was also found to be significantly associated with the
SHR of endocarditis recurrence (SHR = 2.61, 95% CI 1.62 to 4.18, P < 0.001) at the
bivariate level.
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4.6.2

Multivariate Fine–Gray subdistribution hazard regression
analyses for recurrent endocarditis

Results of the multivariate regression analyses are displayed in Table 4.6. PICC line
misuse was found to be significantly associated with the adjusted SHR (CCA: P = 0.001,
FCS: P = 0.002). That is, PICC line misuse was associated with an increase of 2.5 to 2.6
(CCA: SHR = 2.60, 95% CI 1.47 to 4.58; FCS: SHR = 2.50, 95% CI 1.41 to 4.43) in the
rate of recurrent endocarditis in patients who are either event‐free or have experienced a
competing event. Moreover, PICC line misuse was associated with an increase in
incidence of recurrent endocarditis.
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Table 4.6 Bivariate and multivariate Fine–Gray subdistribution hazard regression for recurrent infective endocarditis in
PWID with consideration for death as a competing risk

Age
Sex (ref = female)
Length of hospital stay
Location of infection (ref = right-sided IE)
Left-sided
Bilateral
PICC line misuse (ref = no misuse)
Referral to addiction services (ref = not referred)
Surgical intervention (ref = no surgery)
Admission to the ICU (ref = not admitted)
Misuse of Opiates and Stimulants (ref = opiate or
stimulant use only)
Left AMA (ref = did not leave AMA)

SHR
0.99
1.02
1.01

Bivariate Analysis
95% CI
P-value
0.97 1.02
0.63
0.65 1.60
0.94
1.00 1.01
< 0.001

CCA Multivariate Analysis
SHRa
95% CI
P-value
1.00
0.97 1.03
0.93
1.71
0.99 2.97
0.06
1.00
1.00 1.01
0.17

FCS Multivariate Analysis
SHRa
95% CI
P-value
1.00
0.97 1.03
0.90
1.31
0.76 2.25
0.33
1.00
1.00 1.01
0.21

0.65
1.39
2.61
1.55
0.86
1.26

0.35
0.58
1.62
0.99
0.47
0.78

1.20
3.33
4.18
2.45
1.58
2.04

0.17
0.46
< 0.001
0.06
0.63
0.35

0.78
1.59
2.60
1.20
1.00
1.47

0.36
0.52
1.47
0.70
0.49
0.83

1.67
4.92
4.58
2.07
2.06
2.60

0.52
0.42
0.001
0.50
1.00
0.19

0.76
1.58
2.50
1.27
0.95
1.40

0.36
0.58
1.41
0.77
0.47
0.80

1.59
4.27
4.43
2.09
1.93
2.45

0.46
0.37
0.002
0.35
0.89
0.25

0.89

0.55

1.44

0.64

0.75

0.41

1.35

0.33

0.70

0.40

1.22

0.21

1.15

0.67

1.97

0.61

0.94

0.51

1.76

0.85

1.09

0.60

1.98

0.78

Values in bold indicate statistical significance (P < 0.05).
Abbreviations: CCA, complete case analysis; FCS, fully conditional specification; SHR, subdistribution hazard ratio; CI, confidence interval; PICC, peripherally
inserted central catheter; ICU, intensive care unit; AMA, against medical advice.
a

Adjusted SHRs were generated from multivariable Fine–Gray regression models. The CCA and FCS models were adjusted for age, sex, length of hospital stay,

location of infection, PICC line misuse, referral to addiction services, surgical intervention, ICU admission, substance misused and leaving AMA.
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To further investigate the association between PICC line misuse and endocarditis
recurrence, the cumulative incidence function stratified by PICC line misuse status was
plotted (Figure 4.4). The plot demonstrates a substantial difference in cumulative
incidence of recurrent endocarditis among patients who misused their PICC line and
those who did not. From the plot, it can be seen that the incidence of disease recurrence
was substantially higher in patients who misused their PICC line (0.63 versus 0.32).

Figure 4.4 Cumulative incidence plot of recurrence stratified by PICC line misuse
status among PWID, with consideration for death as a competing risk

4.7 Kaplan–Meier failure function for mortality
Since recurrent endocarditis is not a terminal event and does not impede the observation
of death as an outcome of interest, traditional Kaplan–Meier methods were used for
estimating the probability of mortality among PWID with endocarditis. Of the 310
patients in the study, 99.4% (308/310) had complete data for mortality or long-term
patient follow-up. Of the 308 patients, 66.2% (204/308) were censored and 33.8%
(104/308) died. Figure 4.5 illustrates the Kaplan–Meier failure function estimate for
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death among PWID. The results shown in Figure 4.5 demonstrate an estimated
cumulative incidence for death among PWID of 0.26 (95% CI 0.16 to 0.39) at 139
months.

Figure 4.5 Estimated Kaplan–Meier curve of the cumulative failure function for
death

4.8 Time-dependent Cox proportional-hazards analysis for
death
4.8.1

Bivariate time-dependent Cox proportional-hazards analysis
for death

The overall mortality rate among the study population was observed to be 33.7%
(104/308). Of the patients who died, 41.3% (43/104) experienced a recurrent episode of
endocarditis. Results of the bivariate analyses assessing the relationships between
mortality and predictors of interest are demonstrated in Table 4.7. At the bivariate level,
age at time of admission was found to be significantly associated with mortality among
PWID with endocarditis (HR = 1.04, 95% CI 1.00 to 1.07, P = 0.03). That is, the hazard
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of mortality is 4% greater per year increase in a patient’s age at the time they are
admitted to the acute care hospital. In addition, misuse of polysubstances was found to be
significantly associated with the hazard of mortality (HR = 0.51, 95% CI 0.25 to 1.01, P
= 0.05). Furthermore, the hazard of mortality was found to be significantly higher among
PWID who were admitted to the ICU compared to PWID who were not admitted (HR =
2.04, 95% CI 1.03 to 4.06, P = 0.04). Moreover, surgical intervention was found to
significantly increase the hazard of mortality among PWID (HR = 2.85, 95% CI 1.28 to
6.31, P = 0.01).

4.8.2

Multivariate time-dependent Cox proportional-hazards
analyses for death

An adjusted time-dependent Cox proportional-hazards model was used to evaluate the
association between death and covariates of interest. Results of the multivariate timedependent Cox proportional-hazards regression analyses are displayed in Table 4.7. To
avoid immortal time bias, surgical intervention and recurrent endocarditis were treated as
time-dependent covariates. Furthermore, results of the Schoenfeld test of proportionalhazards assumption found that all other covariates used in the model satisfy the
proportional-hazards assumption (Appendix E).
The results in Table 4.7 demonstrate strong evidence for the association between death
and PICC line misuse (CCA: P = 0.01, FCS: P = 0.007). This result suggests that the risk
of mortality among patients who misused their PICC line was 3.00 to 3.21 (CCA: HR =
3.00, 95% CI 1.29 to 7.00; FCS: HR = 3.21, 95% CI 1.37 to 7.53) times higher than
patients who did not misuse their PICC lines. Additionally, the results demonstrate a 2.15
to 2.33 increase in the risk of mortality (CCA: HR = 2.33, 95% CI 1.05 to 5.19, P = 0.04,
FCS: HR = 2.15, 95% CI 1.00 to 4.63, P = 0.05) among patients who were admitted to
the ICU compared to those who were not. Moreover, the CCA model suggests that
surgical intervention was not significantly associated with the risk of mortality among
PWID (P = 0.19) while the FCS model demonstrates a significant association between
surgical intervention and mortality (P = 0.05).
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Table 4.7 Bivariate and multivariate time-dependent Cox proportional-hazards regression for long-term mortality in PWID

Age
Sex (ref = female)
Length of hospital stay
Right-sided infection (ref = Yes)
PICC line misuse (ref = no misuse)
Referral to addiction services (ref = not referred)
Surgical intervention
Recurrent endocarditis
Admission to the ICU (ref = not admitted)
Misuse of Opiates and Stimulants (ref = opiate or
stimulant use only)
Left AMA (ref = did not leave AMA)

HR
1.04
1.42
1.01
1.46
1.87
1.23
2.85
1.18
2.04

Bivariate Analysis
95% CI
P-value
1.00
1.07
0.03
0.73
2.78
0.31
1.00
1.02
0.18
0.72
2.94
0.29
0.95
3.67
0.07
0.62
2.45
0.55
1.28
6.31
0.01
0.27
5.24
0.83
1.03
4.06
0.04

CCA Multivariate Analysis
HRa
95% CI
P-value
1.03
0.99
1.07
0.20
1.59
0.74
3.38
0.23
1.00
0.99
1.01
0.59
0.86
0.36
2.02
0.73
3.00
1.29
7.00
0.01
1.14
0.53
2.48
0.74
1.96
0.72
5.33
0.19
0.91
0.19
4.29
0.91
2.33
1.05
5.19
0.04

FCS Multivariate Analysis
HRa
95% CI
P-value
1.03
0.99
1.07
0.15
1.37
0.65
2.88
0.41
1.00
0.99
1.01
0.93
0.84
0.36
1.93
0.67
3.21
1.37
7.53
0.007
1.17
0.56
2.45
0.68
2.52
1.01
6.28
0.05
1.09
0.24
5.01
0.91
2.15
1.00
4.63
0.05

0.51

0.25

1.01

0.05

0.61

0.29

1.24

0.17

0.53

0.26

1.08

0.08

0.52

0.20

1.34

0.17

0.53

0.19

1.48

0.23

0.58

0.21

1.60

0.29

Values in bold indicate statistical significance (P < 0.05).
Abbreviations: CCA, complete case analysis; FCS, fully conditional specification; HR, hazard ratio; CI, confidence interval; PICC, peripherally inserted central
catheter; ICU, intensive care unit; AMA, against medical advice.
a

Adjusted HRs were generated from time-dependent multivariable Cox proportional hazards regression models. The CCA and FCS models were adjusted for age,

sex, length of hospital stay, right-sided infection, PICC line misuse, referral to addiction services, surgical intervention, ICU admission, substance misused and
leaving AMA.
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The Kaplan–Meier failure function for death was stratified by PICC line misuse status to
explore the relationship between mortality and PICC line misuse among PWID (Figure
4.6). The Kaplan–Meier survival plot illustrates a considerable decrease in the probability
of survival among patients who misused their PICC line compared to those who did not;
0.61 versus 0.85, respectively, from 65 months onwards.

Figure 4.6 Kaplan–Meier plot of the cumulative survival stratified by PICC line
misuse status among PWID
Similarly, the Kaplan–Meier failure function for death was stratified by ICU admission
status to explore the relationship between mortality and ICU admission among PWID
(Figure 4.7). The Kaplan–Meier survival plot illustrates a considerable decrease in the
probability of survival among patients who were admitted to the ICU compared to those
who did not; 0.63 versus 0.82, respectively, from 65 months onwards.
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Figure 4.7 Kaplan–Meier plot of the cumulative survival stratified by ICU
admission status among PWID
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Chapter 5

5

Discussion

This chapter discusses the study findings, their implications and conclusions made.
Section 5.1 discusses the key findings presented in the study and their implications. The
strengths and limitations of the study are evaluated in Sections 5.2 and 5.3, respectively.
Finally, study conclusions and future directions are discussed in Section 5.4.

5.1 Overview and interpretation of study findings
This is the first study, to our knowledge, that assesses the probability of recurrent
endocarditis among PWID while accounting for competing risks. Additionally, to our
knowledge, this is the first study that evaluates the effects of predictors on mortality
specifically among PWID with endocarditis. The three main objectives of this study were
to (1) characterize important factors that contribute to the recurrence of endocarditis
among PWID in London, Ontario, (2) assess the probability of disease recurrence in the
presence of competing risks among PWID in London, Ontario, and (3) evaluate the
associations of survival time and predictor variables among PWID in London, Ontario.
The following sections outline the key findings of the study and how they relate to
current knowledge.

5.1.1

PICC line misuse

PICC line misuse was observed to be the primary factor significantly associated with the
odds and hazard of developing recurrent endocarditis as well as the hazard of mortality
among PWID. Significant differences in the distribution of PICC line misuse were
observed across strata of PWID who only experienced a single episode of endocarditis
and PWID who went on to experience ≥ two episodes of endocarditis. Among the PWID
in this study, PICC line misuse was observed at a higher frequency among PWID who
went on to experience ≥ two episodes of endocarditis. Study results demonstrated
significant associations between PICC line misuse and the odds of developing recurrent
endocarditis at the bivariate and multivariate levels. The results of the bivariate logistic
analysis of PICC line misuse and recurrent endocarditis in this study differs from current
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literature; a study conducted by Rodger et al.7 did not find a significant association
between PICC line misuse and recurrent endocarditis at the bivariate level. However,
when accounting for other variables in their multivariate analysis, Rodger et al.7 observed
a significant increase in odds of developing recurrent endocarditis among patients who
misused their PICC line, which aligns with the results found in the current study.
In their previous study, Rodger et al.7 did not account for the effects of survival time and
competing risks on the development of recurrent endocarditis. A novel aspect of this
study is (1) the use of the Fine–Gray model to assess the impact of survival time and
death as a competing risk on the rate of endocarditis recurrence, and (2) using a timedependent Cox proportional-hazards model to assess the impact of survival time on the
rate of mortality. When assessing the rate of endocarditis recurrence, PICC line misuse
was observed to be significantly associated with an increase in rate of endocarditis
recurrence with consideration for death as a competing risk at both the bivariate and
multivariate levels. Conversely, when assessing the relationship between PICC line
misuse and the rate of mortality among PWID, PICC line misuse was not observed to be
significantly associated with an increased rate of mortality. However, when adjusting for
the other variables in the model, PICC line misuse was observed to significantly increase
the rate of mortality among PWID.

5.1.2

Length of hospital stay

The distribution of length of hospital stay was observed to significantly differ between
PWID who only experienced a single episode of endocarditis and PWID who went on to
experience ≥ two episodes of endocarditis. This finding is not consistent with current
literature. A single study by Huang et al.14 assessed the distribution of length of hospital
stay between patients who experienced a single endocarditis episode and patients who
went on to experience recurrent endocarditis episodes. From their study, Huang et al.,14
found no significant difference between the distribution of length of hospital stay
between the two strata. However, due to the smaller sample size in the study by Huang et
al.,14 the model may not have had sufficient power to detect differences.
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Current literature has not modelled the relationship between the length of patient hospital
stay and recurrent endocarditis among PWID. Despite looking at the distribution of
length of hospital stay, Huang et al.,14 did not model the relationship. Thus, a novel
aspect of this study is the inclusion of length of hospital stay in the regression model.
Bivariate analysis of the relationship between length of hospital stay and recurrent
endocarditis illustrated a significant positive association, however, when accounting for
other variables in the model, this association was no longer observed. This may be due to
the fact that, in some instances, hospital stay may have been prolonged due to factors that
may make the patient more likely to relapse, such as unstable behaviour, unstable
housing, and mental health issues.
A similar association was observed when assessing the relationship between length of
hospital stay and the rate of endocarditis recurrence. Furthermore, when assessing the
relationship between the length of hospital stay and the hazard of mortality, no
association was observed.

5.1.3

Echocardiography

The distribution of tricuspid valve vegetation differed significantly between PWID who
only experienced a single episode of endocarditis and PWID who went on to experience
≥ two episodes of endocarditis. This result aligns with that found by Huang et al.14, who
observed a significant difference in vegetation of the tricuspid valve among first and
second episodes of endocarditis. In addition, this study found significant differences in
the distribution of left-sided infection across strata of PWID who only experienced a
single episode of endocarditis and PWID who went on to experience ≥ two episodes of
endocarditis. Results of this study demonstrated PWID with left-sided infection had a
significant decrease in the odds of developing recurrent endocarditis compared to PWID
with right-sided endocarditis infection in bivariate analyses. However, this association
was no longer significant after accounting for the other variables in the model. The result
of the bivariate analysis differs from that seen in the literature. Rodger et al.7 found no
significant association between the odds of developing recurrent endocarditis and leftsided infection at the bivariate level.
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Moreover, the results of the current study did not observe a significant difference in the
distribution of bilateral infection across strata. Furthermore, the results failed to
demonstrate an association between bilateral infection and the odds of developing
recurrent endocarditis at both the bivariate and multivariate levels. These results align
with that seen in the literature. Rodger et al.7 found no significant association between the
odds of developing recurrent endocarditis and bilateral infection at the bivariate and
multivariate levels.
When assessing the association between the location of infection (left-sided and bilateral
infection) and the hazards of recurrent endocarditis and mortality, no association was
observed.

5.1.4

Referral to addiction services

This study observed a significant positive association between referral to addiction
services and recurrent endocarditis at the bivariate level. The findings of the current study
could suggest that PWID who went on to experience ≥ two episodes of endocarditis could
be on the higher end of the addiction spectrum than PWID who only experienced a single
episode of endocarditis. Moreover, this finding implies that addiction treatment alone is
not sufficient for decreasing the odds of experiencing recurrent endocarditis. Results of
the bivariate analysis of the current study differs from that seen in the study by Rodger et
al.,7 who observed an insignificant association between addiction services and recurrent
endocarditis. This finding may be the result of low statistical power as a small proportion
of patients were referred to addiction services during their first episode.7 When
controlling for other variables in the model, the current study failed to observe a
significant association between referral to addiction services and recurrent endocarditis,
which is consistent with existing literature. When assessing the association between
referral to addiction services and the hazards of recurrent endocarditis and long-term
mortality, no association was observed. Data on patient follow-up with addiction service
attendance within a community setting was unavailable. Therefore, it is plausible that the
lack of follow-up may have negatively affected the long-term impact of addiction
services on the development of recurrent endocarditis and mortality. In addition, in-
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patient counselling was not randomly assigned, therefore, patients with more severe
addiction may have been referred.

5.1.5

Surgical intervention

The distribution of surgical intervention did not significantly differ between PWID who
only experienced a single episode of endocarditis and PWID who went on to experience
≥ two episodes of endocarditis. In contrast, Huang et al.14 observed a significantly larger
proportion of patients who went on to experience a recurrent episode had undergone
surgical intervention. In comparison to the current study, a larger proportion of PWID
who went on to experience a recurrent episode of endocarditis in the study by Huang et
al.14 underwent surgical intervention (59.1% versus 17.6%), which may explain the
discrepancy seen between the two studies. Results of the current study found no
association between surgical intervention and the odds of developing recurrent
endocarditis at the bivariate or multivariate levels. Furthermore, the study failed to
observe an association between surgical intervention and the hazard of developing
recurrent endocarditis. However, when assessing the association between surgical
intervention and mortality, the current study observed PWID who underwent surgical
intervention were found to have a significantly increased risk of mortality than those who
did not undergo surgical intervention, under FCS model assumptions. This discrepancy
implies that the missing data reduced statistical power and led to biased results by
excluding valuable information that was provided by incomplete observations. When
assessing the association between surgical intervention and the hazards of recurrent
endocarditis and mortality, no association was observed. Although deemed statistically
insignificant, the positive associations between PWID who underwent surgical
intervention and the odds of developing recurrent endocarditis and hazard of mortality
observed in the current study are clinically significant and align with current knowledge;
surgical intervention is not recommended to PWID as they are more susceptible to
disease recurrence and death.7 In contrast, the findings by Rodger et al.7 do not align with
current knowledge as they observed a decrease in adjusted odds of recurrent endocarditis
among PWID who underwent surgical intervention compared to those who did not
undergo surgical intervention.

71

5.1.6

Admission to the ICU

A novel aspect of this study was the evaluation of ICU admittance on recurrent
endocarditis and mortality. The distribution of ICU admittance was not significantly
different between PWID who only experienced a single episode of endocarditis and
PWID who went on to experience ≥ two episodes of endocarditis. Similar distribution
results were observed by Huang et al.14 Furthermore, this study did not observe
significant associations between admission to the ICU and the odds of developing
recurrent endocarditis on the bivariate and multivariate levels. Moreover, admission to
the ICU was not observed to be significantly associated with the hazard of developing
recurrent endocarditis. However, admission to the ICU was observed to be significantly
associated with the hazard of mortality, which aligns with the hypothesis that admission
to the ICU will result in worse patient prognosis.

5.1.7

Age at time of admission

Current literature states that PWID with endocarditis tend to be younger, with a mean and
median age between 20 and 40.8 years.3,4,7,11,14,30,66–68,71 The results found in the current
study align with the current literature with a median age falling in the aforementioned
range. The distribution of age at time of admission was similar between PWID who only
experienced a single episode of endocarditis and PWID who went on to experience ≥ two
episodes of endocarditis. Similar results for age distribution across strata was observed by
Huang et al.14 Current literature has not assessed the associations between age at time of
admission, recurrent endocarditis, and mortality among PWID with endocarditis. The
current study failed to find associations between age at time of admission and the odds of
developing recurrent endocarditis at the bivariate and multivariate levels. Furthermore,
age at time of admission was also not observed to be significantly associated with the
hazards of recurrent endocarditis and mortality.

5.1.8

Sex

Endocarditis is observed more frequently in literature among male patients than female
patients among both non-PWID and PWID, resulting in a 2:1 ratio.6,9,16,65–67 The results
of the current study found the distribution of endocarditis to be similar among male and
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female PWID, rather than a 2:1 ratio. Furthermore, the distribution of sex was not
significantly different between PWID who only experienced a single episode of
endocarditis and PWID who went on to experience ≥ two episodes of endocarditis.
Similar results for the distribution of sex was observed in the study by Huang et al.14
Current literature has not assessed the associations of sex on recurrent endocarditis and
mortality among PWID with endocarditis. The findings of the current study failed to
observe a significant association between sex and the odds of developing recurrent
endocarditis on the bivariate and multivariate levels. Furthermore, sex was also found to
not be associated with the hazards of developing recurrent endocarditis and mortality.

5.1.9

Substance misuse

The distribution of substance type misused was similar between PWID who only
experienced a single episode of endocarditis and PWID who went on to experience ≥ two
episodes of endocarditis. The current study failed to find associations between substance
type misused and the odds of developing recurrent endocarditis at the bivariate and
multivariate levels. Current literature has not assessed the associations between substance
type misused and the hazard of developing recurrent endocarditis and mortality among
PWID with endocarditis. The current study failed to observe a significant association
between substance type misused and the hazards of recurrent endocarditis and mortality.
Conversely, a study by Kimmel et al.147 observed reduced mortality in PWID patients
with IDU-related endocarditis who received medication for opioid use disorder.
However, this association was only observed within the month the medication was
received,147 which was likely due to poor retention. Further studies need to be conducted
to ascertain this relationship.

5.1.10

Leaving against medical advice

The distribution of PWID who left against medical advice did not significantly differ
between PWID who only experienced a single episode of endocarditis and PWID who
went on to experience ≥ two episodes of endocarditis. The current study failed to observe
significant associations between leaving against medical advice and the odds of
developing recurrent endocarditis at the bivariate and multivariate level. Similar results
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were observed by Rodger et al.7 However, the findings of the two studies may be the
result of low statistical power as a low proportion of patients left against medical advice
among first episodes. Current literature has not assessed the associations between leaving
against medical advice and the hazard of recurrent endocarditis and mortality among
PWID with endocarditis. The current study found leaving against medical advice was not
significantly associated with the hazard of developing recurrent endocarditis and
mortality.

5.2 Study strengths
This study has many strengths, including:
Case definition. This study used data on definite endocarditis cases that were reviewed by
several Infectious Disease Specialists and determined using the prescribed Modified
Duke Criteria.17,26
Sample size. This study has the largest study sample of unique PWID (n = 310)
compared to the two other identified studies by Rodger et al.7 (n = 212) and Huang et
al.14 (n = 22)
Missing data. Another strength of this study is the methods used to remediate missing
data. This study conducted analyses using both the CCA and FCS imputation methods to
ensure missing data does not heavily affect the results.
Accounting for immortal time bias. Since the time at risk for the Cox proportionalhazards regression analyses was from hospital discharge from first admission to death,
surgery and hospital readmission for recurrent endocarditis cases varied with time.
Therefore, this study accounted for immortal time bias in the Cox proportional-hazards
regression analyses by incorporating surgery and recurrent endocarditis as timedependent covariates.
Innovation. This is the first study, to our knowledge, to assess the probability of
endocarditis recurrence among the IDU population with consideration for death as a
competing risk. The study used the Fine–Gray model to assess the probability of
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endocarditis recurrence. In comparison to the traditional Kaplan–Meier model, the Fine–
Gray method is a more sophisticated approach to evaluating patient survival by
considering the possibilities of competing risks. By using the Fine–Gray model, this
study found survival estimates that were not overestimated. In addition, this study is the
first, to our knowledge, to evaluate the effects of covariates on mortality among PWID
with endocarditis.

5.3 Study limitations
The study was subjected to several limitations, such as:
Consistency of data collection. One limitation is the use of hospital data and the need to
rely on the consistency of data collection and documentation. Hospital datasets do not
always collect data systematically.148 The collection of hospital data is often done by
several individuals, which may result in discrepancies of data collection.148 For example,
data on the type of substance misused was collected using either self-report, which can be
subjected to recall bias, or via urine toxicology assays. Consequently, there may be some
variability in the accuracy of responses as some data rely on self report and others rely on
urine toxicology. In addition, patient misuse of PICC lines may have been underestimated
as healthcare professionals may not always be aware of the misuse or may not always
document it.
Study entry. The database used for this study did not have access to information
regarding the date of antibiotic therapy completion. Therefore, patient time at risk was
defined from discharge from first admission to the occurrence of an event in an attempt to
ensure bias did not arise due to immortal time. However, a better point of study entry
would be date of admission.
Negative echocardiography. Patients with endocarditis infection may not have abnormal
echocardiography. In this study, several observations for location of infection were coded
as missing data. However, it is expected that these missing data consist of patients with a
negative (normal) echocardiogram.
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Left truncation. Left truncation is a form of censoring in survival analysis whereby the
period between time origin and entry into the cohort is not observed.107 In this study, left
truncation occurred when patients who died prior to discharge from the first admission
were excluded from the study as they were ineligible for reinfection, which may have
produced selection bias and reduced the precision and accuracy of the study.107,149
Limited demographic variables. Demographic variables used in this study consisted of
age and sex. Information on patient ethnicity are not captured in medical charts in
Canada,150 therefore, it was not feasible to include ethnicity as a covariate.
Magnitude of covariates on overall incidence. One limitation of the Fine–Gray
subdistribution hazard regression model is that the magnitude of effect of the predictors
of interest on the overall incidence of endocarditis recurrence can not be directly
quantified from the model.135 Therefore, although one can assume that if PICC line
misuse increases the SHR it also increases the cumulative incidence of endocarditis
recurrence, it can not be concluded that the effect size of PICC line misuse on the SHR is
the same as the effect size of PICC line misuse on the incidence of endocarditis
recurrence.135
Time-dependent covariates in Fine–Gray analyses. Another limitation to this study was
the lack of consideration for potential time-dependent covariates in the Fine–Gray
analyses. Statistical software such as SAS, Stata and R have the ability to include timedependent covariates in the Fine–Gray subdistribution hazard model. However, inclusion
of time-dependent covariates restricts the interpretation of the relationship between the
model covariates and the CIF.136 Consequently, future studies that consider timedependent covariates using the Fine–Gray subdistribution hazard model should be
conducted with caution.136

5.4 Implications for policy and practice
The results of this study demonstrate that PICC line misuse is significantly associated
with endocarditis recurrence and mortality and may be an indicator of severe addiction.
While PICC line misuse may be remediated by continuous monitoring of PWID, this
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solution is neither feasible nor practical. Therefore, public health prevention efforts
should aim to address the underlying issue of PICC line misuse—addiction and stigma.
IDU is highly stigmatized, which negatively impacts PWID and often results in poorer
health outcomes compared to non-PWID.59 Stigma and discrimination towards IDU can
occur in several ways: (1) internally, whereby PWID apply negative messages and
connotations to themselves, (2) socially, whereby negative connotations regarding IDU is
applied through media and the community, and (3) structurally, whereby negative
stereotypes regarding IDU are applied by healthcare providers and public service
workers.59,151 Internal stigma and discrimination may affect PWID’s health-seeking and
injection behaviours.152 Socially, stigma regarding IDU consists of the negative
stereotype whereby PWID are viewed as having control over their addiction and blamed
for their actions.153 Social stigma negatively impacts a PWID’s ability to access adequate
medical and social supports and use of safe injection practices.152 Structural stigma may
include negative attitudes of healthcare providers, which results in poor communication
and reduced therapeutic relationship between healthcare providers and PWID, which may
significantly contribute to disease recurrence.152
Public health strategies to improve the barriers produced by stigma and discrimination,
such as education and training, need to be implemented. Internal stigma may be mitigated
by better informing PWID about their right to access services.151 At the social level,
education can address the problematic language used to describe addiction and IDU, and
create a person-first narrative.59,154 Currently, limited education is given to healthcare
providers regarding the prevention and treatment of infectious diseases among PWID.152
Furthermore, there are inadequate strategies to decrease stigma at the structural level.153
To remediate the issues seen at the structural level, education programs for healthcare
providers should focus on the prevention of diseases among PWID and the intricacy of
substance use disorders as a whole.151 Furthermore, appropriate guidelines for treatment
of serious infectious diseases among PWID need to be developed. The use of PICC lines
in PWID is an enduring issue; some healthcare providers adhere to the moral imperative
to provide all patients with standard care despite being identified as PWID, whereas other
healthcare providers view the use of PICC lines as medically negligent due to the risks
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they impose.152 Consequently, treatment of PWID with infectious diseases should be
person-centred. In contrast to patient-centred treatment, which is focused on a patient’s
medical condition, person-centred care focuses on a patient’s issues with consideration
for their multimorbidity.155,156

5.5 Conclusions
This study identifies PICC line misuse as a leading risk factor for recurrent endocarditis
and mortality among PWID. Furthermore, this study identified admission to the ICU and
surgical intervention as additional risk factors for mortality among PWID with
endocarditis. Treatment of endocarditis among PWID is more difficult than among nonPWID as the recommended treatment guidelines are not always appropriate for this
marginalized population. By identifying PICC line misuse as a leading predictor for
recurrent endocarditis among PWID, clinicians are able to target prevention strategies
towards patients who are more likely to misuse their PICC line. Furthermore, due to the
high recurrence and mortality rates associated with prosthetic valve endocarditis, these
prevention efforts can also aid surgeons and patients in informed decision-making
regarding valve replacement surgery. Further research should be conducted to explore
suitable treatments for endocarditis among PWID.
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Appendix C Literature search strategy
Database

Endocarditis terms

Injection drug terms

MEDLINE

(repeat endocarditis or repeat infective endocarditis or repeat

(injection drug user* or intravenous drug user* or IUD* or

infectious endocarditis or recurrent endocarditis or recurrent

drug user* or persons who inject drugs or people who inject

infective endocarditis or recurrent infectious endocarditis).ti,ab.

drugs or PWID or injector* or drug injector* or injecting drug

Results
9

user* or injecting drug abuse* or injection drug user* or
injection drug abuse* or drug utilization or intravenous
substance abuse* or intravenous substance user*).ti.
Embase

(repeat endocarditis or repeat infective endocarditis or repeat

(injection drug user* or intravenous drug user* or IUD* or

infectious endocarditis or recurrent endocarditis or recurrent

drug user* or persons who inject drugs or people who inject

infective endocarditis or recurrent infectious endocarditis).ti,ab.

drugs or PWID or injector* or drug injector* or injecting drug

15

user* or injecting drug abuse* or injection drug user* or
injection drug abuse* or drug utilization or intravenous
substance abuse* or intravenous substance user*).ti.
Web of

TI=((repeat endocarditis) or (repeat infective endocarditis) or (repeat

TI=((injection drug user*) or (intravenous drug user*) or

Science

infectious endocarditis) or (recurrent endocarditis) or (recurrent

IUD* or (drug user*) or (persons who inject drugs) or (people

infective endocarditis) or (recurrent infectious endocarditis)) or

who inject drugs) or PWID or injector* or (drug injector*) or

AB=((repeat endocarditis) or (repeat infective endocarditis) or

(injecting drug user*) or (injecting drug abuse*) or (injection

(repeat infectious endocarditis) or (recurrent endocarditis) or

drug user*) or (injection drug abuse*) or (drug utilization) or

(recurrent infective endocarditis) or (recurrent infectious

(intravenous substance abuse*) or (intravenous substance

endocarditis))

user*))

18
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Appendix D Assessing violations of the proportional hazards assumption for the
outcome recurrent endocarditis
The proportional hazards assumption assumes that the effect of each covariate on the
hazard ratio does not vary with time.157 The following Cox model is assumed for
assessing the association between the risk of recurrent endocarditis and exposure
variables. The assumption of proportional hazards is discussed and tested subsequently.
log[ℎ(𝑡|𝑥)] = log[ℎ0 (𝑡)] + 𝛽1 𝑎𝑔𝑒 + 𝛽2 𝑠𝑒𝑥 + 𝛽3 𝐿𝑂𝑆 + 𝛽4 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛 + 𝛽5 𝑠𝑢𝑟𝑔𝑒𝑟𝑦 + 𝛽6 𝑃𝐼𝐶𝐶
+ 𝛽7 𝑎𝑑𝑑𝑖𝑐𝑡𝑖𝑜𝑛 + 𝛽8 𝐴𝑀𝐴 + 𝛽9 𝑠𝑢𝑏𝑠𝑡𝑎𝑛𝑐𝑒 + 𝛽10 𝐼𝐶𝑈

Of the 310 patients used in the study, under the assumption of the Cox proportionalhazards model, 76.1% (236/310) were censored and 23.9% (74/310) experienced a
recurrent episode (second episode) of endocarditis. Supplementary Table 1 shows the
results of the Schoenfeld tests of proportional hazards assumption.
Supplementary Table 1 Schoenfeld tests of proportional hazards assumption
Age
Sex
Female
Male
Length of hospital stay
Location of infection
Right sided
Left sided
Bilateral
Addiction services referral
No
Yes
PICC misuse
No
Yes
Substance misuse
Opiate or stimulant only
Polysubstance
ICU admission
No
Yes
Surgical intervention
No
Yes
Left AMA
No

rho

χ2

df

P-value

-0.11

0.81

1.00

0.37

Reference
0.13
0.17

1.37
2.65

1.00
1.00
1.00

0.24
0.10

Reference
-0.01
-0.03

0.02
0.06

1.00
1.00
1.00

0.90
0.81

Reference
-0.10

0.84

1.00
1.00

0.36

Reference
-0.28

5.81

1.00
1.00

0.02

Reference
0.02

0.03

1.00
1.00

0.87

Reference
0.17

2.20

1.00
1.00

0.14

Reference
-0.20

2.70

1.00
1.00

0.10

Reference

-

1.00

-
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Yes

rho
-0.02

χ2

df

0.03

1.00

P-value
0.86

Global Test
16.65
11.00
0.12
Abbreviations: PICC, peripherally inserted central catheter; ICU, intensive care unit; AMA, against
medical advice.

The results of the Schoenfeld Residuals test demonstrate strong evidence of a declining
relationship between the log-hazard ratio and PICC line misuse (rho = –0.28, P = 0.016).
To evaluate the extent of assumption violation, scaled Schoenfeld residuals for PICC line
misuse against time were plotted (Supplementary Figure 1).

Supplementary Figure 1 Smoothed estimate of log-hazard ratio for PICC line
misuse
From Supplementary Figure 1, it was determined that there are few estimates past 30
months (few patients went 30 months without having experienced recurrent endocarditis).
Limited information is available after 30 months, making it difficult to assess model
assumptions and could also result in large variance of the resulting estimates. Therefore,
patients who experienced an event after 30 months were artificially censored to relax
model assumption and improve estimation efficiency. Supplementary Table 2 illustrates
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the results of the Schoenfeld tests of proportional hazards assumption where time-toevent > 30 months was artificially censored.
Supplementary Table 2 Schoenfeld tests of proportional hazards assumption where
time-to-event > 30 months is artificially censored
Age
Sex
Female
Male
Length of hospital stay
Location of infection
Right sided
Left sided
Bilateral
Addiction services referral
No
Yes
PICC misuse
No
Yes
Substance misuse
Opiate or stimulant only
Polysubstance
ICU admission
No
Yes
Surgical intervention
No
Yes
Left AMA
No
Yes

rho
0.03

χ2
0.06

df
1.00

P-value
0.81

Reference
0.01
0.22

0.01
4.16

1.00
1.00
1.00

0.94
0.04

Reference
0.06
-0.11

0.23
0.92

1.00
1.00
1.00

0.63
0.34

Reference
-0.01

0.01

1.00
1.00

0.91

Reference
-0.12

1.02

1.00
1.00

0.31

Reference
0.08

0.53

1.00
1.00

0.47

Reference
0.09

0.60

1.00
1.00

0.44

Reference
-0.09

0.50

1.00
1.00

0.45

Reference
-0.16

1.81

1.00
1.00

0.18

Global Test
10.51
11.00
0.49
Abbreviations: PICC, peripherally inserted central catheter; ICU, intensive care unit; AMA, against
medical advice.

The results in Supplementary Table 2 show that PICC line misuse no longer violates the
proportional hazards assumption. To further investigate, scaled Schoenfeld residuals for
PICC line misuse against time with artificial censoring were plotted (Supplementary
Figure 2).
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Supplementary Figure 2 Smoothed estimate of log-hazard ratio for PICC line
misuse with artificial censoring of time-to-event >30 months
The results in Supplementary Table 2 and Supplementary Figure 2 do not demonstrate
strong evidence that PICC line misuse violates the assumption of proportional hazards.
Therefore, we conducted the survival analyses for evaluating the risk of recurrent
endocarditis based on the Cox model defined previously.
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Appendix E Assessing violations of the proportional hazards assumption for the
outcome death
Of the 308 patients with complete data for death status and long-term follow-up, under
the assumption of the Cox proportional-hazards model, 66.2% (204/308) were censored
and 33.8% (104/308) died. Supplementary Table 3 shows the results of the Schoenfeld
tests of proportional hazards assumption. The results of the Schoenfeld Residuals test fail
to demonstrate strong evidence of a significant violation of the proportional hazards
assumption.
Supplementary Table 3 Schoenfeld tests of proportional hazards assumption
Age
Sex
Female
Male
Length of hospital stay
Location of infection
Right sided
Left sided
Bilateral
Addiction services referral
No
Yes
PICC misuse
No
Yes
Substance misuse
Opiate or stimulant only
Polysubstance
ICU admission
No
Yes
Recurrent endocarditis
No
Yes
Surgical intervention
No
Yes
Left AMA
No
Yes

rho

χ2

df

P-value

0.07

0.19

1

0.66

Reference
-0.18
-0.02

1.09
0.01

1
1
1

0.30
0.91

Reference
0.27
0.42

2.06
0.00

1
1
1

0.15
1.00

Reference
-0.20

1.24

1
1

0.27

Reference
-0.16

0.89

1
1

0.35

Reference
0.08

0.24

1
1

0.63

Reference
-0.20

1.37

1
1

0.24

Reference
0.24

1.85

1
1

0.17

Reference
-0.10

0.35

1
1

0.55

Reference
-0.22

1.73

1
1

0.19

Global Test
10.63
12.00
0.62
Abbreviations: PICC, peripherally inserted central catheter; ICU, intensive care unit; AMA, against
medical advice.

98

Curriculum Vitae
Name

Janica Adams

Post-secondary
Education and
Degrees

The University of Western Ontario
London, Ontario, Canada
2019–2021 M.Sc. Epidemiology and Biostatistics
The G. Raymond Chang School of Continuing Education,
Ryerson University
Toronto, Ontario, Canada
2018–2019 Certificate in Occupational Health and Safety
Ryerson University
Toronto, Ontario, Canada
2013–2018 B.Sc. (Honours) Biomedical Science

Honours and
Awards

Western Graduate Research Scholarship (WGRS)
2019–2021
Dean’s list
2017–2018

Related Work
Experience

Health Analyst
Informatics
Public Health Ontario
March 2021–Present
R Workshop Co-Instructor
Department of Epidemiology and Biostatistics
Western University
2020–2021
Research Assistant
Department of Epidemiology and Biostatistics
Western University
2019–Present

Conference
Posters and
Presentations

Adams JA, Dawson EC, Dhinsa T, Wootten J, Wilk P. (2020).
Differences in mental health service use among white and nonwhite immigrants to Canada. Poster presented at: Joint Mental
Health Research and Innovation Day 2020

